[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 11076
1. Ohno H: Pathogenetic and clinical implications of non-immunoglobulin ; BCL6 translocations in B-cell non-Hodgkin's lymphoma. J Clin Exp Hematop; 2006 Nov;46(2):43-53

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathogenetic and clinical implications of non-immunoglobulin ; BCL6 translocations in B-cell non-Hodgkin's lymphoma.
  • Chromosomal translocations affecting band 3q27, where BCL6 gene is located, are among the most common genetic abnormalities in non-Hodgkin's lymphoma of B-cell type (B-NHL).
  • The 3q27/BCL6 translocation is unique in that it can involve not only immunoglobulin (Ig) genes but also non-Ig chromosomal loci as a partner.
  • To date, around 20 non-Ig partner genes have been identified.
  • As a result of non-Ig ; BCL6 translocations, many types of regulatory sequences of each partner gene substitute for the 5' untranslated region of BCL6, and the rearranged BCL6 comes under the control of the replaced promoter.
  • The introduction of non-Ig ; BCL6 constructs into transformed cells led to high-level Bcl-6 protein expression in the nucleus, while BCL6 mRNA levels in clinical materials of diffuse large B-cell lymphoma (DLBCL) with non-Ig ; BCL6 translocations were unexpectedly low.
  • A comparative study suggested that non-Ig ; BCL6 translocation and a low level of BCL6 mRNA expression are concordant indicators of a poor clinical outcome in cases of DLBCL.
  • The coexistence of a non-Ig ; BCL6 translocation with t(14 ; 18)(q32 ;.
  • q21) in a single clone did not significantly affect the clinical features of follicular lymphoma.
  • The pathogenetic and clinical implications of non-Ig ; BCL6 translocations in B-NHL subtypes may not be identical to those of Ig ; BCL6.
  • [MeSH-major] DNA-Binding Proteins / genetics. Genetic Markers. Lymphoma, B-Cell / genetics. Translocation, Genetic / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17142954.001).
  • [ISSN] 1346-4280
  • [Journal-full-title] Journal of clinical and experimental hematopathology : JCEH
  • [ISO-abbreviation] J Clin Exp Hematop
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Genetic Markers
  • [Number-of-references] 62
  •  go-up   go-down


2. Tumwine LK, Orem J, Kerchan P, Byarugaba W, Pileri SA: EBV, HHV8 and HIV in B cell non Hodgkin lymphoma in Kampala, Uganda. Infect Agent Cancer; 2010;5:12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EBV, HHV8 and HIV in B cell non Hodgkin lymphoma in Kampala, Uganda.
  • BACKGROUND: B cell non Hodgkin lymphomas account for the majority of lymphomas in Uganda.
  • The commonest is endemic Burkitt lymphoma, followed by diffuse large-B-cell lymphoma (DLBCL).
  • There has been an increase in incidence of malignant lymphoma since the onset of the HIV/AIDS pandemic.
  • To describe the prevalence of Epstein-Barr virus, Human Herpes virus 8 and Human Immunodeficiency Virus-1 in B cell non Hodgkin lymphoma biopsy specimens in Kampala, Uganda.2.
  • To describe the histopathology of non Hodgkin lymphoma by HIV serology test result in Kampala, Uganda METHOD: Tumour biopsies specimens from 119 patients with B cell non Hodgkin lymphoma were classified according to the WHO classification.
  • Real time and nested PCR were used for the detection of HIV.The patients from whom the 1991-2000 NHL biopsies had been taken did not have HIV serology results therefore 145 patients biopsies where serology results were available were used to describe the association of HIV with non Hodgkin lymphoma type during 2008-2009.
  • RESULTS: In this study, the majority (92%) of the Burkitt lymphomas and only 34.8% of the diffuse large B cell lymphomas were EBV positive.
  • None of the precursor B lymphoblastic lymphomas or the mantle cell lymphomas showed EBV integration in the lymphoma cells.None of the Burkitt lymphoma biopsies had HIV by PCR.
  • Of the 121 non Hodgkin B cell lymphoma patients with HIV test results, 19% had HIV.
  • However, only 1(0.04%) case of Burkitt lymphoma had HIV.
  • CONCLUSIONS: The majority of the Burkitt lymphomas and two fifths of the diffuse large B cell lymphomas had EBV.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AIDS. 1991 Jun;5(6):669-74 [1652978.001]
  • [Cites] Blood. 2009 Feb 5;113(6):1213-24 [18955561.001]
  • [Cites] Rev Epidemiol Sante Publique. 1980 Oct 30;28(3):307-21 [6258200.001]
  • [Cites] Eur J Cancer Clin Oncol. 1983 Oct;19(10):1393-404 [6315443.001]
  • [Cites] Baillieres Clin Haematol. 1995 Mar;8(1):165-99 [7663046.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Apr 1;8(4):379-85 [7882103.001]
  • [Cites] Cancer Res. 1994 Apr 15;54(8):2069-72 [8174106.001]
  • [Cites] Int J Cancer. 1993 Apr 22;54(1):26-36 [8478145.001]
  • [Cites] J Exp Med. 1996 May 1;183(5):2385-90 [8642350.001]
  • [Cites] Hum Pathol. 1997 Mar;28(3):367-74 [9042803.001]
  • [Cites] Hum Pathol. 1997 Sep;28(9):1026-33 [9308726.001]
  • [Cites] Int J Cancer. 1998 Sep 11;77(6):817-20 [9714046.001]
  • [Cites] AIDS. 1998 Oct 1;12(14):1921-5 [9792393.001]
  • [Cites] Hum Pathol. 1998 Nov;29(11):1285-9 [9824108.001]
  • [Cites] N Engl J Med. 1999 Nov 11;341(20):1520-9 [10559454.001]
  • [Cites] Br J Cancer. 2000 May;82(9):1585-92 [10789729.001]
  • [Cites] J Natl Cancer Inst. 1977 May;58(5):1191-6 [192894.001]
  • [Cites] AIDS. 2000 Dec 22;14(18):2929-36 [11153674.001]
  • [Cites] J Virol. 2001 Feb;75(4):1857-63 [11160684.001]
  • [Cites] Int J Cancer. 2003 Sep 1;106(3):388-95 [12845679.001]
  • [Cites] Int J Cancer. 2004 Jan 1;108(1):66-70 [14618617.001]
  • [Cites] Curr HIV Res. 2004 Jul;2(3):215-21 [15279585.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):757-68 [15510157.001]
  • [Cites] PLoS Biol. 2005 Dec;3(12):e404 [16277553.001]
  • [Cites] J Infect Dis. 2006 Feb 1;193(3):422-6 [16388490.001]
  • [Cites] J Gen Virol. 2006 May;87(Pt 5):1047-74 [16603506.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 3;103(40):14935-40 [17001014.001]
  • [Cites] Oncogene. 2007 Aug 2;26(35):5115-23 [17325665.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1358-64 [17873116.001]
  • [Cites] Hum Pathol. 2008 Jun;39(6):817-23 [18436278.001]
  • [Cites] J Clin Virol. 2008 Nov;43(3):255-9 [18723390.001]
  • [Cites] Semin Cancer Biol. 2009 Dec;19(6):411-20 [19897039.001]
  • [Cites] AIDS. 2010 Feb 20;24(4):479-90 [20051807.001]
  • [Cites] Hum Pathol. 2007 Feb;38(2):308-14 [17097130.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3813-20 [18230756.001]
  • [Cites] BMC Infect Dis. 2008;8:111 [18706107.001]
  • [Cites] Adv Cancer Res. 1990;55:133-270 [2166998.001]
  • (PMID = 20591151.001).
  • [ISSN] 1750-9378
  • [Journal-full-title] Infectious agents and cancer
  • [ISO-abbreviation] Infect. Agents Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2907314
  •  go-up   go-down


3. Badin F, Hayslip J: Rituximab in the treatment of B-cell non-Hodgkin lymphoma, focus on outcomes and comparative effectiveness. Clinicoecon Outcomes Res; 2010;2:37-45

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab in the treatment of B-cell non-Hodgkin lymphoma, focus on outcomes and comparative effectiveness.
  • Rituximab is an important and well established component in the treatment of many patients with B-cell non-Hodgkin lymphoma.
  • In this paper we review recent clinical trials investigating the addition of rituximab to standard chemotherapy regimens for treatment of patients with diffuse large B cell lymphoma and follicular lymphoma.
  • More uniquely, we review economic aspects of lymphoma treatments, including the cost of standard chemotherapy regimens with or without rituximab, cost effectiveness of rituximab in both induction and maintenance treatment, and lymphoma's impacts on patient's productivity and their caregivers.
  • We conclude that adding rituximab to standard chemotherapy treatment for patients with B-cell non-Hodgkin lymphoma is safe and cost-effective in numerous settings during both induction and maintenance therapies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3121-7 [16754935.001]
  • [Cites] Eur J Cancer. 2001 Sep;37(14):1781-9 [11549432.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):268-76 [10458242.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1 Suppl 2):2-9 [11842383.001]
  • [Cites] Blood. 2004 Feb 1;103(3):777-83 [12907446.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3064-71 [15284112.001]
  • [Cites] N Engl J Med. 2005 Feb 3;352(5):441-9 [15689582.001]
  • [Cites] Eur J Haematol. 2005 Mar;74(3):194-202 [15693788.001]
  • [Cites] Cancer. 2005 Mar 15;103(6):1292-301 [15700265.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1644-51 [15756658.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2240-7 [15800314.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3725-32 [16123223.001]
  • [Cites] Blood. 2006 Jan 1;107(1):265-76 [16150940.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):379-91 [16648042.001]
  • [Cites] Ann Oncol. 2006 May;17 Suppl 4:iv25-30 [16702181.001]
  • [Cites] J Clin Oncol. 2002 Oct 15;20(20):4261-7 [12377971.001]
  • [Cites] Br J Haematol. 2003 Apr;121(1):44-8 [12670330.001]
  • [Cites] Blood. 2004 May 15;103(10):3684-8 [14739217.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4416-23 [14976046.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4117-26 [15867204.001]
  • [Cites] Haematologica. 2005 May;90(5):661-71 [15921381.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5027-33 [15955905.001]
  • [Cites] Value Health. 2005 Jul-Aug;8(4):462-70 [16091023.001]
  • [Cites] Ann Hematol. 2006 Aug;85(8):530-4 [16639571.001]
  • [Cites] Lancet Oncol. 2008 Feb;9(2):105-16 [18226581.001]
  • [Cites] Leuk Lymphoma. 2008 Feb;49(2):227-36 [18231908.001]
  • [Cites] Value Health. 2008 Mar-Apr;11(2):221-30 [18380634.001]
  • [Cites] Acta Oncol. 2008;47(6):1029-36 [18607857.001]
  • [Cites] Clin Lymphoma Myeloma. 2008 Jun;8(3):166-70 [18650180.001]
  • [Cites] Bone Marrow Transplant. 2009 May;43(9):701-8 [19029963.001]
  • [Cites] J Clin Oncol. 2009 Apr 1;27(10):1607-14 [19255334.001]
  • [Cites] Cochrane Database Syst Rev. 2009;(2):CD006552 [19370640.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3295-301 [16873669.001]
  • [Cites] Cochrane Database Syst Rev. 2008;(1):CD004024 [18254036.001]
  • [Cites] J Clin Oncol. 2008 Sep 20;26(27):4473-9 [18626004.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4579-86 [18662969.001]
  • [Cites] Ann Hematol. 2009 Jan;88(1):51-7 [18665360.001]
  • [Cites] J Clin Oncol. 2008 Nov 10;26(32):5156-64 [18854568.001]
  • [Cites] Psychooncology. 2009 May;18(5):554-9 [18942670.001]
  • [Cites] J Clin Oncol. 2009 Mar 10;27(8):1202-8 [19204203.001]
  • [Cites] Bone Marrow Transplant. 1997 Nov;20(10):889-96 [9404932.001]
  • (PMID = 21935313.001).
  • [ISSN] 1178-6981
  • [Journal-full-title] ClinicoEconomics and outcomes research : CEOR
  • [ISO-abbreviation] Clinicoecon Outcomes Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3169958
  • [Keywords] NOTNLM ; cost effectiveness / lymphoma / rituximab / safety / transplant
  •  go-up   go-down


Advertisement
4. Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM: Attenuation of CD8(+) T-cell function by CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin's lymphoma. Cancer Res; 2006 Oct 15;66(20):10145-52
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Attenuation of CD8(+) T-cell function by CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin's lymphoma.
  • The underlying mechanisms by which tumor cells are resistant to CTL-mediated apoptosis are not clear.
  • Using a human model of B-cell non-Hodgkin's lymphoma (B-cell NHL), we show that intratumoral T(reg) cells inhibit the proliferation and granule production of activated autologous infiltrating CD8(+) T cells.
  • Our results also show that degranulation and subsequent cytotoxic activity of infiltrating CD8(+) T cells exposed to lymphoma B cells is completely attenuated by the presence of intratumoral T(reg) cells.
  • Furthermore, we show that increased numbers of intratumoral T(reg) cells correlates with the number of CD8(+) T cells in biopsy specimens from patients with B-cell NHL, supporting the in vitro findings that intratumoral T(reg) cells inhibit proliferation of infiltrating CD8(+) T cells.
  • Taken together, these data indicate that human lymphoma B cells are sensitive to autologous CTL-mediated cell death but are protected by the inhibitory function of intratumoral T(reg) cells.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2000 Dec;14(12):2149-58 [11187905.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):720-6 [11157023.001]
  • [Cites] J Immunol Methods. 2001 Jul 1;253(1-2):177-87 [11384679.001]
  • [Cites] Blood. 2001 Aug 15;98(4):1070-7 [11493453.001]
  • [Cites] Blood. 2002 Jan 1;99(1):232-7 [11756176.001]
  • [Cites] Br J Haematol. 2002 Nov;119(2):425-31 [12406081.001]
  • [Cites] Nat Immunol. 2002 Dec;3(12):1208-13 [12415266.001]
  • [Cites] Science. 2003 Feb 14;299(5609):1057-61 [12522256.001]
  • [Cites] Nat Immunol. 2003 Apr;4(4):330-6 [12612578.001]
  • [Cites] Nat Immunol. 2003 Apr;4(4):337-42 [12612581.001]
  • [Cites] Cancer Immunol Immunother. 2003 Jul;52(7):423-8 [12695859.001]
  • [Cites] J Immunol Methods. 2003 Oct 1;281(1-2):65-78 [14580882.001]
  • [Cites] J Clin Invest. 2004 Jan;113(2):310-7 [14722622.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1755-62 [14604957.001]
  • [Cites] Annu Rev Immunol. 2004;22:745-63 [15032595.001]
  • [Cites] Blood. 2004 Jun 1;103(11):4251-8 [14976040.001]
  • [Cites] Nat Med. 2004 Sep;10(9):942-9 [15322536.001]
  • [Cites] Immunity. 2004 Oct;21(4):589-601 [15485635.001]
  • [Cites] J Immunol. 1995 Aug 1;155(3):1382-92 [7636203.001]
  • [Cites] Cancer Immunol Immunother. 1995 Sep;41(3):175-84 [7553687.001]
  • [Cites] Cell Immunol. 1996 Jul 10;171(1):10-9 [8660832.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Feb 3;95(3):1178-83 [9448305.001]
  • [Cites] Blood. 1998 Apr 15;91(8):2875-85 [9531598.001]
  • [Cites] Cancer Res. 1999 Jul 1;59(13):3128-33 [10397255.001]
  • [Cites] N Engl J Med. 2004 Nov 18;351(21):2159-69 [15548776.001]
  • [Cites] J Immunol Methods. 2004 Nov;294(1-2):15-22 [15604012.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):419-24 [15623559.001]
  • [Cites] J Immunol. 2005 Mar 1;174(5):2591-601 [15728465.001]
  • [Cites] J Exp Med. 2005 Mar 7;201(5):779-91 [15753211.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):263-74 [15776005.001]
  • [Cites] Hepatology. 2005 Apr;41(4):722-30 [15791620.001]
  • [Cites] Leukemia. 2005 May;19(5):835-40 [15744340.001]
  • [Cites] J Virol. 2005 Jun;79(12):7852-9 [15919939.001]
  • [Cites] J Virol. 2005 Jun;79(12):7860-7 [15919940.001]
  • [Cites] Breast Cancer Res Treat. 2005 Jul;92(1):85-93 [15980996.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2018-25 [15914560.001]
  • [Cites] Blood. 2006 Jan 1;107(1):301-4 [16150935.001]
  • [Cites] Blood. 2006 Jan 15;107(2):628-36 [16179369.001]
  • [Cites] Blood. 2006 Apr 1;107(7):2871-8 [16339406.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 25;103(17):6659-64 [16617117.001]
  • [Cites] Blood. 2006 May 15;107(10):3940-9 [16410445.001]
  • [Cites] J Immunol. 2006 Jun 1;176(11):6586-93 [16709816.001]
  • [Cites] Blood. 2006 May 1;107(9):3639-46 [16403912.001]
  • [Cites] J Immunol. 1999 Nov 15;163(10):5211-8 [10553041.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):3904-9 [11051236.001]
  • (PMID = 17047079.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA97274; United States / NCI NIH HHS / CA / R01 CA092104; United States / NCI NIH HHS / CA / CA92104; United States / NCI NIH HHS / CA / CA097274-060004; United States / NCI NIH HHS / CA / P50 CA097274; United States / NCI NIH HHS / CA / R01 CA092104-05A2; United States / NCI NIH HHS / CA / P50 CA097274-060004; United States / NCI NIH HHS / CA / CA092104-05A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / Interleukin-2 Receptor alpha Subunit; 0 / Membrane Glycoproteins; 0 / Pore Forming Cytotoxic Proteins; 126465-35-8 / Perforin; EC 3.4.21.- / GZMB protein, human; EC 3.4.21.- / Granzymes
  • [Other-IDs] NLM/ NIHMS89147; NLM/ PMC2680600
  •  go-up   go-down


5. Arif A, Jamal S, Mushtaq S, Ahmed S, Mubarik A: Frequency of bcl-2 gene rearrangement in B-cell Non-Hodgkin's lymphoma. Asian Pac J Cancer Prev; 2009 Apr-Jun;10(2):237-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequency of bcl-2 gene rearrangement in B-cell Non-Hodgkin's lymphoma.
  • OBJECTIVE: The objective of the study was to determine the frequency of bcl-2 gene rearrangement in B-cell Non-Hodgkin's lymphoma (NHL) and identify different breakpoints of bcl-2 gene.
  • METHODS: Thirty cases of B-cell lymphoma (including 8 cases of follicular lymphoma, 19 cases of diffuse large B-cell lymphoma and 3 cases of T-cell rich B-cell lymphoma) were included in the study.
  • The polymerase chain reaction was done for major break point region (mbr), minor cluster region (mcr) and intermediate cluster region (icr) of the bcl-2 gene.
  • RESULTS: The bcl-2 gene rearrangement was identified in 23.3% of B-cell lymphoma, 50% of follicular lymphoma, 15% of diffuse large B-cell lymphoma and no bcl-2 rearrangement was identified in any of the T-cell rich B-cell lymphomas.
  • Further analysis showed the icr breakpoint in 16.7% of B-cell lymphoma, 37.5% of follicular lymphoma and 10.5% of diffuse large B-cell lymphoma.
  • Involvement of the mbr breakpoint was found in 6.7% of B-cell lymphoma, 12.5% of follicular lymphoma, and 5.3% of diffuse large B-cell lymphoma.
  • CONCLUSION: The bcl-2 gene rearrangement is quite frequent in follicular lymphoma, followed by diffuse large B-cell lymphoma.
  • This indicates that primers for bcl-2 gene must include icr primer, whenever the bcl-2 gene is being evaluated for B-cell NHL in this part of the world and this might reduce the variability of frequency of bcl-2 gene rearrangement within and between different regions.
  • [MeSH-major] Gene Rearrangement, B-Lymphocyte. Genes, bcl-2 / genetics. Lymphoma, Non-Hodgkin / genetics
  • [MeSH-minor] Female. Humans. Lymphoma, B-Cell / genetics. Lymphoma, Follicular / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Male. Middle Aged. Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19537891.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


6. Soufla G, Baritaki S, Sifakis S, Zafiropulos A, Spandidos DA: Transcriptional inactivation of p53, Bax, Bcl-2 and Mdm2 correlates with malignant transformation of the uterine cervix. Int J Biol Markers; 2005 Jan - Mar;20(1):18-27
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcriptional inactivation of p53, Bax, Bcl-2 and Mdm2 correlates with malignant transformation of the uterine cervix.
  • : Deregulation of the apoptotic machinery plays a major role in cell death, cellular transformation and cancer. p53, Bcl-2, Bcl-XL, Bax and Mdm2 mRNA expression patterns were evaluated in tissue samples with cervical intraepithelial neoplasia (CIN) and cervical cancer compared to those of normal cervical tissues, and correlated with the underlying cervical lesions.
  • Transcript levels of the above genes were assessed by RT-PCR analysis in a total of 44 cervical specimens. p53, Bcl-2, Bax and Mdm2 transcript levels were significantly different in the normal, CIN and cancer specimen groups (p=0.003, p=0.009, p=0.040 and p=0.001, respectively).
  • Specifically, p53, Bax and Bcl-2 exhibited substantially lower transcript levels in CIN lesions compared to controls, whereas Bax mRNA levels showed a significant decrease in cancer compared to normal specimens.
  • High-grade squamous intraepithelial lesions exhibited lower p53 and Bcl-2 mRNA levels than controls (p=0.002, p=0.016).
  • Coexpression analysis revealed more correlations between the above apoptosis-related molecules in normal tissues compared to CIN or cancer specimens. p53 showed significant coexpression with Bax, Bcl-2 and Mdm2 (p=0.040, p=0.013 and p=0.015, respectively) in normal cervical specimens.
  • Bax and Bcl-XL mRNA expression was negatively correlated.
  • Mdm2 transcriptional levels correlated significantly with those of Bax, Bcl-XL and Bcl-2.
  • Our findings show that p53, Bax, Bcl-2 and Mdm2 mRNA expression levels correlate with the malignant transformation of the uterine cervix. mRNA coexpression patterns of the members of the pro- and anti-apoptotic family examined in cervical carcinogenesis were found to be disrupted in CIN and cancer, as already demonstrated at the protein level. (Int J Biol Markers 2005; 20: 18-27).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28207100.001).
  • [ISSN] 1724-6008
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


7. Williams LE, DeNardo GL, Meredith RF: Targeted radionuclide therapy. Med Phys; 2008 Jul;35(7Part1):3062-3068

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Uptake, in percent-injected dose per gram of malignant tissue, is used to evaluate the specificity of the targeting vehicle.
  • Lymphoma (B-cell) has been the primary clinical application.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2008 American Association of Physicists in Medicine.
  • (PMID = 28513035.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Anatomy / Auger effect / Cancer / Computed tomography / Conformal radiation treatment / Dosimetry / Medical imaging / Positron emission tomography / Positron emission tomography (PET) / Proteins / Single photon emission computed tomography / Single photon emission computed tomography (SPECT) / Tissue engineering / Tissues / absorbed dose / alpha-particle sources / antibodies / beta-ray sources / blood / cellular biophysics / positron emission tomography / radiation therapy / radioisotopes / radionuclide therapy / single photon emission computed tomography / tumours
  •  go-up   go-down


8. Levine B, Sinha SC, Kroemer G: Bcl-2 family members: Dual regulators of apoptosis and autophagy. Autophagy; 2008 Jul 01;4(5):600-606
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bcl-2 family members: Dual regulators of apoptosis and autophagy.
  • In normal conditions, Beclin 1 is bound to and inhibited by Bcl-2 or the Bcl-2 homolog Bcl-X<sub>L</sub>.
  • This interaction involves a Bcl-2 homology 3 (BH3) domain in Beclin 1 and the BH3 binding groove of Bcl-2/Bcl-X<sub>L</sub>.
  • Other proteins containing BH3 domains, called BH3-only proteins, can competitively disrupt the interaction between Beclin 1 and Bcl-2/Bcl-X<sub>L</sub> to induce autophagy.
  • Nutrient starvation, which is a potent physiologic inducer of autophagy, can stimulate the dissociation of Beclin 1 from its inhibitors, either by activating BH3-only proteins (such as Bad) or by posttranslational modifications of Bcl-2 (such as phosphorylation) that may reduce its affinity for Beclin 1 and BH3-only proteins.
  • Thus, anti-apoptotic Bcl-2 family members and pro-apoptotic BH3-only proteins may participate in the inhibition and induction of autophagy, respectively.
  • This hitherto neglected crosstalk between the core machineries regulating autophagy and apoptosis may redefine the role of Bcl-2 family proteins in oncogenesis and tumor progression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28186856.001).
  • [ISSN] 1554-8635
  • [Journal-full-title] Autophagy
  • [ISO-abbreviation] Autophagy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Wang M, Zhou Y, Zhang L, Nguyen CA, Romaguera J: Use of bortezomib in B-cell non-Hodgkin's lymphoma. Expert Rev Anticancer Ther; 2006 Jul;6(7):983-91
Hazardous Substances Data Bank. BORTEZOMIB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of bortezomib in B-cell non-Hodgkin's lymphoma.
  • The ubiquitin-proteasome pathway plays a critical role in the regulated degradation of proteins involved in cell cycle control and tumor growth.
  • In preclinical studies, bortezomib has demonstrated activity against a variety of B-cell malignancies by inducing apoptosis and sensitizing tumor cells to radiation or chemotherapy.
  • Based on these findings, clinical trials have been conducted with bortezomib in B-cell non-Hodgkin's lymphoma.
  • In these studies, bortezomib was generally well tolerated with manageable toxicities and showed promising clinical activity.
  • Mantle cell lymphoma was significantly more sensitive to bortezomib than other non-Hodgkin's lymphomas.
  • Bortezomib may have far-reaching potential in the treatment of B-cell non-Hodgkin's lymphoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Boronic Acids / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Pyrazines / therapeutic use
  • [MeSH-minor] Bortezomib. Clinical Trials as Topic. Humans. Lymphoma, Follicular / drug therapy. Multiple Myeloma / drug therapy. Waldenstrom Macroglobulinemia / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16831071.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  • [Number-of-references] 51
  •  go-up   go-down


10. Briones J: Emerging therapies for B-cell non-Hodgkin lymphoma. Expert Rev Anticancer Ther; 2009 Sep;9(9):1305-16
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Emerging therapies for B-cell non-Hodgkin lymphoma.
  • In recent years considerable progress has been made in the treatment of patients with B-cell non-Hodgkin lymphoma (NHL).
  • In recent years, the knowledge of the cellular and molecular biology of distinct types of B-cell NHL have led to the development of a new class of drugs that specifically targets unique disease-specific pathways.
  • This review will focus on novel therapies that are being developed for the treatment of B-cell NHL including those targeting the B-cell receptor signaling pathway, the proteasome, epigenetic lesions, novel anti-apoptotic drugs, new monoclonal antibodies and immunomodulatory drugs.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Drug Delivery Systems. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal / pharmacology. Antibodies, Monoclonal / therapeutic use. Apoptosis / drug effects. Clinical Trials as Topic. Humans. Signal Transduction / drug effects

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19761434.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents
  • [Number-of-references] 107
  •  go-up   go-down


11. Nowakowski GS, Witzig TE: Radioimmunotherapy for B-cell non-Hodgkin lymphoma. Clin Adv Hematol Oncol; 2006 Mar;4(3):225-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radioimmunotherapy for B-cell non-Hodgkin lymphoma.
  • Radioimmunotherapy is an established and effective treatment in B-cell non-Hodgkin lymphoma (NHL).
  • Currently, two radioimmunoconjugates (RICs) are approved for clinical use in the United States, ibritumomab tiuxetan and tositumomab.
  • Both agents target the CD20 antigen on B-cell lymphoma cells.
  • [MeSH-major] Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / radiotherapy. Radioimmunotherapy / methods

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16728934.001).
  • [ISSN] 1543-0790
  • [Journal-full-title] Clinical advances in hematology & oncology : H&O
  • [ISO-abbreviation] Clin Adv Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD20
  • [Number-of-references] 33
  •  go-up   go-down


12. Visser OJ, Zijlstra JM, van Dongen GA, Huijgens PC: [Radio-immunotherapy for B-cell non-Hodgkin lymphoma]. Ned Tijdschr Geneeskd; 2005 Oct 15;149(42):2324-8
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Radio-immunotherapy for B-cell non-Hodgkin lymphoma].
  • [Transliterated title] Radio-immunotherapie bij het B-cel-non-hodgkinlymfoom.
  • Radio-immunotherapy is a new treatment modality for patients with B-cell non-Hodgkin lymphoma.
  • Clinical studies, notably in patients with indolent non-Hodgkin lymphoma, have demonstrated the clinical feasibility and efficacy of this treatment.
  • The use of a high dose ofradio-immunotherapy in combination with (high-dose) chemotherapy and peripheral stem-cell transplantation constitutes a supplemental treatment for patients who respond insufficiently or not at all to standard therapy.
  • The exact place of radio-immunotherapy in the treatment of patients with non-Hodgkin lymphomas is not yet clear.
  • [MeSH-major] Lymphoma, B-Cell / radiotherapy. Radioimmunotherapy / methods

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Ned Tijdschr Geneeskd. 2005 Oct 15;149(42):2350-4 [16261716.001]
  • (PMID = 16261710.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Comment; English Abstract; Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 13
  •  go-up   go-down


13. Robertson MJ, Kline J, Bauman J, Gardner O, Jonak Z, Koch KM, Murray SC, Weisenbach J, Toso J: A phase I trial evaluating the safety and biological activity of iboctadekin (rhIL-18) in combination with rituximab in patients with CD20+ B-cell non-Hodgkin's lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):8566

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I trial evaluating the safety and biological activity of iboctadekin (rhIL-18) in combination with rituximab in patients with CD20+ B-cell non-Hodgkin's lymphoma.
  • When administered as monotherapy in phase I clinical studies, rhIL-18 was safe, well tolerated and induced potent biological responses (e.g.
  • Th1 cytokine production and expression of activation markers on NK, CD8+ and CD4+ cells).
  • METHODS: Patients with CD20+ B cell non-Hodgkin's lymphoma are being given rituximab (375 mg/m2) IV weekly for 4 consecutive weeks in combination with ascending doses of intravenous rhIL-18 (1 to 100 mcg/kg in 6 cohorts of 3 patients each) IV weekly for 12 weeks to identify a dose that is safe and tolerable and gives a maximum biological effect.
  • Eligible patients must have disease which progressed after standard therapy or for which there is no effective standard treatment.
  • The pharmacodynamic response is as expected with a dose-dependent decrease in circulating activated (CD69+) NK cells within 4 hours after completing the rhIL-18 infusion which rebound to pre-dose levels within 2-4 days.
  • Using the International Working Group response criteria for lymphoma, two subjects had complete responses at 10 and 20 mcg/kg, one subject had a partial response at 10 mcg/kg and three subjects had stable disease at 1, 3 and 3 mcg/kg.
  • This study will define the dose level to be used in a future phase II trial evaluating this combination in patients with relapsed or refractory follicular lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961021.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Belada D, Smolej L, Hrudková M, Štěpánková P, Sýkorová A, Žák P, Bukač J, Malý J: Addition of Rituximab Significantly Improves Outcomes in Patients with Diffuse Large B-cell Lymphoma - a Single-center, Retrospective Study. Acta Medica (Hradec Kralove); 2007;50(2):113-118

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Addition of Rituximab Significantly Improves Outcomes in Patients with Diffuse Large B-cell Lymphoma - a Single-center, Retrospective Study.
  • CHOP chemotherapy has been used as a standard first-line treatment for diffuse large B-cell lymphoma since the 1970s.
  • This single-center, retrospective study was performed to evaluate the role of the addition of R to chemotherapy (CHT) in a real-world clinical setting.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28949910.001).
  • [ISSN] 1211-4286
  • [Journal-full-title] Acta medica (Hradec Kralove)
  • [ISO-abbreviation] Acta Medica (Hradec Kralove)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Czech Republic
  • [Keywords] NOTNLM ; Diffuse large B-cell lymphoma / Immunochemotherapy / Non-Hodgkin’s lymphoma / Rituximab
  •  go-up   go-down


15. Reiter A, Meinhardt A, Burkhardt B, Zimmermann M, Borkhardt A, Kontny U, Mann G, Schrappe M: Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin lymphoma (NHL). J Clin Oncol; 2009 May 20;27(15_suppl):10000

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin lymphoma (NHL).
  • : 10000 Background: Pediatric mature B-cell NHL differ from aggressive B-NHL of adults in terms of biology and treatment outcome.
  • Exclusion: Lansky performance scale 5, pre-treatment, impaired renal-, heart-, liver-function, hepatitis B, pre-existing disease, pregnancy.
  • RR by histology: BL/B-ALL 29/68, DLBCL 6/14, juvenile follicular lymphoma 1/2, PMBCL 1/1, B-NHL nfs 0/2.
  • Fifty pts were non-RPs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962545.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Ritesh P, Pahuja S, Chavez J, Braddy W, Skipper M, Bernstein ZP, Chanan-Khan A, Ramanarayanan J, Czuczman MS, Hernandez-Ilizaliturri FJ: Correlation of surface expression of CD11b or CD32 in polymorphonuclear cells (PMNs) and CD69 in natural killer cells (NK) with progression-free survival (PFS) following chemoimmunotherapy with rituximab and liposomal doxorubicin (LD) in patients (pts) with relapsed or refractory B-cell lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):8583

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of surface expression of CD11b or CD32 in polymorphonuclear cells (PMNs) and CD69 in natural killer cells (NK) with progression-free survival (PFS) following chemoimmunotherapy with rituximab and liposomal doxorubicin (LD) in patients (pts) with relapsed or refractory B-cell lymphoma.
  • FcγRIIIa polymorphisms have been associated with clinical responses to rituximab.
  • To this end, we prospectively studied the pre-treatment quality and function of PMNs and NK cells from pts with refractory/relapsed B-cell lymphomas in a Phase I/II trial.
  • Forty-two B-cell lymphoma patients pts completed treatment.
  • Surface expression of CD11b and CD32 in the PMN's correlated with a longer PFS (P = 0.040 and P = 0.015, respectively).There was a non-statistically significant trend towards an improved in PFS in those patients whom their PBMC's exhibited a higher degree of ex-vivo rituximab ADCC.
  • Our data suggest that R+LD is a safe and effective regimen and that the quality of the immune system prior to a chemo-immunotherapy regimen may play a role in clinical outcomes, specifically the expression of CD11b and CD32 in PMNs or CD69 in NKcells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962271.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Fiveash JB, Chowdhary SA, Peereboom D Jr, Mikkelsen T, Nabors LB, Lesser GJ, Rosenfeld MR, Ye X, Grossman SA: NABTT-0702: A phase II study of R-(-)-gossypol (AT-101) in recurrent glioblastoma multiforme (GBM). J Clin Oncol; 2009 May 20;27(15_suppl):2010

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 2010 Background: R-(-)-gossypol (AT-101) is an oral bcl-2 family protein inhibitor (Bcl-2, Bcl-X<sub>L</sub>, Mcl-1, Bcl-W) and potent inducer of proapoptotic proteins.
  • A prior study of racemic gossypol demonstrated objective responses in patients with malignant glioma.
  • METHODS: Fifty-six patients with recurrent GBM were enrolled in this multi-institution phase II clinical trial through the NABTT CNS consortium designed to detect a 33% increase in overall survival (OS, primary endpoint) from 5 to 6.65 months with Power/Alpha 80%/0.01.
  • Seven patients (16%) had stable disease as the best response.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964593.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Pitot HC, Mould D, Maleski J, Leopold L: Analysis of a phase I pharmacokinetic (PK)/food effect study of AT-101 in patients with advanced solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):2557

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 2557 Background: AT-101 is an oral, pan-Bcl-2 inhibitor (Bcl-2, Bcl-XL, Bcl-W, Mcl-1).
  • Overexpression of Bcl-2 family proteins is common in human cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961871.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Sohn B, Yoon D, Kim S, Lee D, Kim S, Huh J, Lee J, Suh C: Outcomes in patients with primary gastric diffuse large B-cell lymphoma after rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) chemotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):e19543

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes in patients with primary gastric diffuse large B-cell lymphoma after rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) chemotherapy.
  • : e19543 Background: The optimal therapy for primary gastric diffuse large B- cell lymphoma (DLBCL) still needs to be defined.
  • METHODS: We searched AMC Registry for Non-Hodgkin's Lymphoma and found 26 patients with primary gastric DLBCL, who received R-CHOP as first-line chemotherapy.
  • Ten of 26 patients had localized disease.
  • Remaining patients had disseminated disease.
  • After analyses of 10 patients with localized disease, we found that these patients had received a total 38 cycles, with a median of 3 cycles per patient.
  • In patients with localized disease, CR was observed in 10 of 10 patients (100%), and both 3-year EFS and OS was 100% (10 of 10 patients).
  • In analyses with 16 patients with disseminated disease, all patients had received a total 91 cycles, with a median of 6 cycles per patient.
  • CR after R-CHOP treatment was observed in 10 of 16 patients (62.5%), partial response in 3 patients, stable disease in 1 patient, and progressive disease in 1 patient.
  • Three-year EFS and OS was 61.1% and 57.8% in patients with disseminated disease.
  • Combination with rituximab in CHOP regimen showed excellent prognosis especially in patients with localized disease.
  • In localized disease, CR was 100%, 3-year EFS and OS was 100%.
  • In disseminated disease, CR was 62.5%, 3-year EFS and OS was 61.1% and 57.8%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960994.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Hensel M, Goetzenich A, Hanhoff N, Wolf E, Knechten H, Mosthaf F: Cancer incidence in HIV-positive patients in Germany: A nation-wide survey from 2000 to 2007. J Clin Oncol; 2009 May 20;27(15_suppl):e22115

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this study was to gather data on the epidemiology of AIDS-defining (AD) and non-AIDS-defining (NAD) malignancies in HIV-positive patients (pts) in Germany in the past decade.
  • The questionnaire requested information on all malignancies in HIV-positive pts, tumor stage, CDC (Center for Disease Control)-stage of the HIV infection, sex, treatment and clinical course.
  • The majority of pts had advanced HIV-disease (CDC stage C3), but the proportion of pts with stage C3 decreased from 58% in 2000 to 36.8% in 2007.
  • 253 (45.8%) were AD as follows: 132 Kaposi Sarcomas, 109 aggressive B-cell lymphomas, 12 invasive cervix carcinomas.
  • The B-cell lymphomas further included 28 Burkitt's lymphomas, 30 DLBCL, 9 Castleman diseases, 8 primary cerebral lymphomas.
  • Among the 299 cases (54.2%) of NAD malignomas were 213 solid tumors including 71 anal carcinomas (= 33.5% of all NAD malignancies) and 85 hemoblastoses including 29 Hodgkin lymphomas (= 9.6% of all NAD malignancies).
  • Interestingly, only 1 of 8 primary cerebral lymphomas has been reported after 2001.
  • The number of pts with Hodgkin's lymphoma has increased constantly from 2000 to 2007.
  • Anal carcinomas and Hodgkin's lymphomas in particular were markedly more prevalent in our HIV-positive cohort compared to published reports of the general population.
  • The incidence of primary cerebral lymphomas seems to decrease, whereas the incidence of Hodgkin's lymphoma is increasing.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963512.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Micallef IN, Maurer MJ, Nikcevich DA, Cannon MW, Schaefer EW, Moore DF, Kurtin P, Witzig TE: Final results of NCCTG N0489: Epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):8508

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Final results of NCCTG N0489: Epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma.
  • : 8508 Background: A prior pilot study of epratuzumab (Immunomedics) and rituximab in combination with CHOP chemotherapy (ER-CHOP) in untreated patients with diffuse large B-cell lymphoma demonstrated feasibility and safety.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960859.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Bower M, Syed N, Papoudou-Bai A, Stebbing J, Naresh K, Hatzimichael E, Powles S, Crook T: Methylation reversal in high-grade B lymphoma cell lines and novel epigenetic changes conserved between immunocompetent and HIV-positive hosts. J Clin Oncol; 2009 May 20;27(15_suppl):8585

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylation reversal in high-grade B lymphoma cell lines and novel epigenetic changes conserved between immunocompetent and HIV-positive hosts.
  • : 8585 Background: Methylation-dependent transcriptional silencing is an important mechanism of tumour suppressor gene inactivation in neoplasia, including lymphoma.
  • METHODS: Pharmacological "unmasking" of transcriptionally silenced genes in B lymphoma cell lines was achieved using 5' deazacytidine ± Trichostatin A and subsequent analysis of mRNA levels on micro-array.
  • Candidate genes thus identified, were further analysed by qPCR, methylation-specific PCR (MSP) and bisulphite sequencing in B lymphoma cell lines and by MSP in clinical samples from sporadic (immunocompetent) (18 cases) and HIV-infected patients (14 cases).
  • Samples in both patient groups were diffuse large B cell lymphoma (DLBCL) and Burkitt's lymphoma (BL).
  • Additionally, we analysed 8 cases of marginal zone lymphoma (MZL) from the immunocompetent group.
  • RESULTS: We report the identification of 13 novel genes, not previously described in the literature, which are subject to methylation-dependent transcriptional silencing in high-grade lymphoma and whose expression can be reactivated by demethylating agents.
  • The frequency of methylation in individual genes varied from approximately 10% to 75% in specific lymphoma subtypes, but was in general similar in high grade lymphomas in immunocompetent and HIV-infected hosts.
  • CONCLUSIONS: Using pharmacological reversal of methylation, we have identified a number of genes, not previously implicated in human neoplasia, which are subject to transcriptional silencing in high-grade B lymphomas.
  • Detection of methylated DNA of one or more of these genes may have utility as biomarkers of clinical outcome in each patient group.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962294.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Doudican NA, Pennell R, Tu T, Liebes L, Pavlick A, Berman R, Shapiro R, Goldberg JD, Osman I, Orlow S: Effect of mebendazole on melanoma xenograft growth through targeting of bcl-2. J Clin Oncol; 2009 May 20;27(15_suppl):9075

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of mebendazole on melanoma xenograft growth through targeting of bcl-2.
  • : 9075 Background: Defects in apoptosis are thought to contribute to melanoma chemoresistance, making the anti-apoptotic protein Bcl-2 an attractive therapeutic target.
  • We identified mebendazole (MBZ), a microtubule binding agent, as an inducer of melanoma cytotoxicity via a Bcl-2 dependent mechanism in vitro (Mol Cancer Res, Aug 2008).
  • In the present study, we assessed the effect of MBZ on human melanoma tumor growth and progression in a mouse xenograft model and compared the ability of MBZ to inhibit growth of cultured melanoma cells to that of oblimersen (OBL), an antisense drug targeting Bcl-2.
  • Bcl-2 phosphorylation was determined by immunoblotting.
  • This reduction in volume was accompanied by a 46% decrease in proliferating cells and an 81% increase in apoptotic cells.
  • Orally administered MBZ treatment resulted in Bcl-2 phosphorylation in vivo, further confirming its mechanism of action.
  • MBZ inhibited growth of melanoma cells in culture more effectively than OBL with GI50 values of 0.32 uM and 7.45 uM, respectively.
  • A phase II clinical trial investigating MBZ's utility as adjuvant therapy in patients with stage IV, resected melanoma is planned.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962178.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Morales D, Beltran B, Hurtado de Mendoza F, Riva L, Quiñones P: Analysis of prognostic factors in patients with EBV positive diffuse large B cell lymphoma of the elderly. J Clin Oncol; 2009 May 20;27(15_suppl):e19542

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of prognostic factors in patients with EBV positive diffuse large B cell lymphoma of the elderly.
  • : e19542 Background: EBV positive diffuse large B cell lymphoma of the elderly is a new entity included in the Fourth edition of WHO Classification.
  • AIM: The goal of this study was to evaluate clinical characteristics and survival of EBV positive diffuse large B cell lymphoma of the elderly from Peruvian patients.
  • METHODS: Between January 2002 and June 2008, eleven patients with EBV positive diffuse large B cell lymphoma of the elderly were included in the analysis.
  • All cases were positive to the presence of EBV encoded RNA (EBER) by CISH and CD20 and/or Pax-5 expression by immunohistochemistry.Clinical data were reviewed retrospectively and patient's biopsies were analyzed for the immunohistochemical expression of BCL6, CD10, CD30 and MUM-1/IRF4 by tissue microarray (TMA) technique..
  • Extranodal disease occurred in 6/11 (54%) patients: pleura (n=2), suprarenal gland (n=1), stomach (n=1), cecum (n=1), bone (1), skin (1) and bone marrow (n=1).
  • Ten cases (83%) were of the Non-GC and 1 case was GC.
  • Complete response (n=2), partial response (n=0) and progressive disease (n=3).
  • CONCLUSIONS: EBV positive diffuse large B cell lymphoma of the elderly was related to high IPI, poor ECOG, frequent extranodal disease, poor response to treatment and very short survival.
  • It is the first report of this entity in a non-Asian population.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960995.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Maraj I, Hernandez-Ilizaliturri FJ, Chisti M, Czuczman MS: Efficacy of the DAC inhibitor LBH589 in both rituximab-sensitive and rituximab-resistant lymphomas and effect on the antitumor activity of chemotherapy agents, monoclonal antibodies, and bortezomib. J Clin Oncol; 2009 May 20;27(15_suppl):8576

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of the DAC inhibitor LBH589 in both rituximab-sensitive and rituximab-resistant lymphomas and effect on the antitumor activity of chemotherapy agents, monoclonal antibodies, and bortezomib.
  • : 8576 Deacetylases (DACs) are enzymes that remove the acetyl groups from target proteins [histones (class I) and non-histones (class II)], leading to regulation of gene transcription and other cellular processes.
  • LBH589 is a novel and potent DAC class I and II Inhibitor undergoing pre-clinical and clinical testing.
  • In order to develop therapeutic options for refractory/resistant B-cell lymphomas we studied the effects of LBH589 in the anti-tumor activity of chemotherapy agents and monoclonal antibodies in a panel of rituximab-sensitive cell lines (RSCL), rituximab-resistant cell lines (RRCL), and in lymphoma cells isolated from patients with treatment-naïve or refractory/relapsed B-cell lymphomas by negative selection using magnetic beads.
  • NHL cells lines were exposed to the following chemotherapy agents or monoclonal antibodies: CDDP, doxorubicin, vincristine, bortezomib or rituximab, veltuzumab, or isotype, alone or in combination with LBH589.
  • Patient-derived tumor cells were exposed to either LBH589, bortezomib or both.
  • Changes in ATP content were determined by cell titer glow assay.
  • RNA was isolated from NHL cell lines exposed to LBH859 and changes in gene expression of the Bcl-2 family members were determined by qualitative polymerase chain reaction (PCR).
  • LBH589 was active as a single agent against RSCL, RRCL or patient-derived tumor cells.
  • In addition, Bcl-XL gene down-regulation was observed following exposure to LBH859.
  • Our data suggests that LBH589 is active against various RSCL, RRCL and patient-derived tumor cells.
  • Findings suggest that LBH589 added to systemic anti-CD20 and/or chemotherapy could result in a novel and potent treatment strategy against B-cell lymphomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962275.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Passalacqua R, Brighenti M, Naldi N, Potenzoni D, Monica B, Fumagalli M, Lazzarelli S, Caminiti C: Long-term effects of a program of bladder preservation using chemotherapy plus radiotherapy in muscle invasive bladder cancer (BC). Analysis of biologic predictive factors and health-related quality of life (QOL). J Clin Oncol; 2009 May 20;27(15_suppl):e16014

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Moreover we investigated whether p53, Ki67, bcl-2, c-erbB-2 protein expression predict the achievement of a complete response (CR).
  • At the response evaluation, pts with biopsy proven residual disease were considered incomplete responders (IR) and underwent immediate cystectomy.
  • Paraffin embedded blocks of the primary tumors were collected and Ki67, p53, bcl-2 and c-erbB-2 protein expression were evaluated in a blind fashion.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962925.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Pavlick AC, Ott P, Escalon J, Madden K, Yepes E, Staha J, Mendoza S, Gandhi A, Yee H, Liebes L: Survival of advanced melanoma patients with normal LDH treated with oblimersen, temozolomide, and nab-paclitaxel. J Clin Oncol; 2009 May 20;27(15_suppl):9080

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 9080 Background: Oblimersen (OBL), temozolomide (TMZ), and abraxane (ABX) act synergistically in preclinical studies with melanoma cell lines.
  • Bcl-2 antisense therapy in combination with dacarbazine was encouraging in advanced melanoma patients(pts) with normal LDH.
  • METHODS: Chemotherapy-naïve advanced melanoma pts (ECOG PS ≤ 2, baseline LDH ≤1.1 × ULN, measurable disease per RECIST) were enrolled on a phase I/II protocol.
  • Immunohistochemical (IHC) staining for Bcl-2, Bcl-XL, BAK and caspase 3 was performed in pre- and post-therapy tumor samples.
  • Disease sites included liver (6), other visceral sites (10), skin, subcutaneous tissue, and lymph nodes (2).
  • Shed cryptic epitopes correlated with clinical response versus disease progression.
  • Alteration of the tumor biology based on phenotypic changes in Bcl-2, Bcl-xL, BAK and caspase 3 correlated with response to treatment.
  • Biomarker studies support the rationale that Bcl-2 antisense therapy specifically impacts apoptotic signaling pathways in melanoma cells from metastatic tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962199.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Flinn IW, Byrd JC, Furman RR, Brown JR, Lin TS, Bello C, Giese NA, Yu AS: Preliminary evidence of clinical activity in a phase I study of CAL-101, a selective inhibitor of the p1108 isoform of phosphatidylinositol 3-kinase (P13K), in patients with select hematologic malignancies. J Clin Oncol; 2009 May 20;27(15_suppl):3543

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary evidence of clinical activity in a phase I study of CAL-101, a selective inhibitor of the p1108 isoform of phosphatidylinositol 3-kinase (P13K), in patients with select hematologic malignancies.
  • The PI3K p110δ isoform is highly expressed in cells of hematopoietic origin and plays a key role in B cell maturation and function.
  • In vitro studies of 0.1 to 10 μM CAL-101 showed inhibition of pAKT expression and/or apoptotic effects against primary chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) cells and against a range of leukemia and lymphoma cell lines.
  • METHODS: In an ongoing phase 1 dose escalation study in sequential cohorts of 3 patients with relapsed/refractory CLL or select B-cell non-Hodgkin's lymphoma, CAL-101 is administered orally twice daily for 28 days per cycle.
  • Clinical response is evaluated according to NCI criteria at the end of Cycles 1 and 2 and every 2 cycles thereafter.
  • Two of 6 patients attained partial response and 4 have stable disease.
  • Partial responses were observed after 2 cycles of 50 mg in a patient with mantle cell lymphoma with 6 prior therapies, and after 1 cycle of 100 mg in a patient with follicular lymphoma with 6 prior therapies, including autologous stem cell transplant.
  • Disease specific cohort expansion will occur at the maximally tolerated dose, and patients with AML will be added.
  • CONCLUSIONS: Early results from a phase 1 study of the oral PI3K p110δ inhibitor CAL-101 show that it is well tolerated and has preliminary clinical activity in patients with B-cell malignancies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961357.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Baum PR, Cerveny C, Gordon B, Nilsson C, Wiens J, Rafiq S, Lapalombella R, Muthusamy N, Byrd JC, Wahl A: Evaluation of the effect of TRU-016, an anti-CD37 directed SMIP in combination with other therapeutic drugs in models of non-Hodgkin's lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):8571

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the effect of TRU-016, an anti-CD37 directed SMIP in combination with other therapeutic drugs in models of non-Hodgkin's lymphoma.
  • : 8571 Background: TRU-016, a single chain anti-CD37 Fc fusion molecule has been shown to display pro-apoptotic and Fc-dependent cellular cytotoxicity activities against primary CLL cells and NHL cell lines.
  • The pro-apoptotic signal generated by TRU-016 binding to CD37 on CLL cells has been shown to be caspase-independent and distinct from the signal generated by many other therapeutics including rituximab.
  • We have tested drug combinations using the mantle cell lymphoma line Rec-1 and diffuse large B-cell lymphoma line SU-DHL-6 in vitro and extended these results to in vivo settings using the follicular lymphoma cell line DOHH2 treated with the combination of TRU-016 and bendamustine.
  • METHODS: To determine TRU-016 interactions with the established therapeutics rituximab, doxorubicin, rapamycin, and bendamustine, drugs were tested alone or in combination with TRU-016 and the anti-proliferative effects on cell lines measured after 96 hours.
  • To determine if in vitro synergy could be recapitulated in vivo, SCID mice were implanted with DOHH2 cells and therapeutic treatment was initiated when tumor volumes reached 200 mm<sup>3</sup>.
  • This demonstrates that the in vitro synergy results were extendable to a more complex in vivo disease model.
  • CONCLUSIONS: TRU-016 in combination with rituximab, rapamycin, or bendamustine increases cell killing of NHL cells.
  • Furthermore, the combination of TRU-016 and bendamustine displayed greater in vivo anti-tumor activity than either agent alone against a follicular lymphoma tumor model.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961015.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Flowers C, Sinha R, Kaufman J, Shenoy P, Lewis C, Bumpers K, Rogatko A: Bortezomib plus modified R-CHOP as initial therapy for indolent B-cell lymphomas: Phase I results. J Clin Oncol; 2009 May 20;27(15_suppl):8577

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bortezomib plus modified R-CHOP as initial therapy for indolent B-cell lymphomas: Phase I results.
  • : 8577 Background: Adding rituximab (R) to chemotherapy improves survival for patients (pts) with follicular lymphoma (FL) and other indolent non-Hodgkin lymphomas (NHL), but not all pts respond.
  • The maximum tolerated dose (MTD) was defined as the regimen at which <30% grade ≥3 non-hematological or grade ≥4 hematological toxicity (>14 days) occurs.
  • This facilitated MTD finding with fewer pts given prior data on B+RCHOP.
  • 6 pts (55%) had stage IV disease; 8 (64%) had FLIPI ≥2.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962274.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Gaffar HA, Elfayomy A, Elmaghraby A, Elnemr MM, Elsawy WH: bcl-2 expression and possibility of bladder preservation using combined modality treatment in muscle-invasive transtional cell carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e16133

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] bcl-2 expression and possibility of bladder preservation using combined modality treatment in muscle-invasive transtional cell carcinoma.
  • To evaluate the combined modality treatment and selective bladder preservation and to evaluate BCL-2 expression that may predict treatment response and survival.
  • METHODS: 66 eligible patients with T2-4a NxM0 transitional cell carcinoma received two courses of gemcitabine and cisplatin followed by 45 Gy of pelvic radiotherapy in 1.8 Gy fractions with concomitant cisplatin.
  • Immunohistochemistry was used to assess the tumor cell expression of BCL-2.
  • Bcl-2 was expressed in 35 (53%) of the patients.
  • Bcl-2 immunoreactivity was inversely correlated with of histological grade (p = 0.0232) and was not correlated with gender distribution (p = 0.4666), the clinical stage (T) (p = 0.4325) or response to treatment (p = 0.6234).
  • No significant difference was noted between the cause-specific survival rate of patients with positive Bcl-2 expression and those with negative BCL-2 expression.
  • CONCLUSIONS: this combined approach of chemotherapy and radiation therapy with bladder preservation should be considered as an option for muscle-invasive transitional cell carcinoma of bladder.
  • Assessment of Bcl-2 protein expression may be used to predict a clinical response to this combined modality approach.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963367.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Lopez R, Gallardo E, Ruibal A, Leon L, Sanchez-Salmon A, Abdulkader I, Gude F, Curiel T, Barandela J, Gayoso L: HIF expression and Max-SUV-18F-FDG-PET in non-small cell lung cancer (NSCLC) patients. J Clin Oncol; 2009 May 20;27(15_suppl):e22010

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIF expression and Max-SUV-18F-FDG-PET in non-small cell lung cancer (NSCLC) patients.
  • WI) to construct a TMA block, according to conventional protocols for the study of immunohistochemical expression of HIF-1α, HIF-2 α, EGFR, bcl-2, MIB1, p16, p63 and cyclins A, B1, D1 and D3.
  • Sections were scored as positive if >10% of cells stained positively.
  • Staining patterns were correlated to clinical variables.
  • RESULTS: HIF- 1α expression was observed in 84/96 patients (34/39 adenocarcinomas and 50/57 squamous cell carcinomas), however it did not correlate with clinical stage (I-II: 41/45 vs III-IV: 44/51).
  • HIF-2 α expression was observed in 60/103 cases (27/42 adenocarcinomas and 33/61 squamous cell carcinomas) and it did not correlate with clinical stage ((I-II: 28/45 vs III-IV: 32/57).
  • After multivariate analysis, only the clinical stage (RR: 2,2) was a prognostic factor. CONCLUSIONS:.
  • 1) HIF-1α and HIF-2 α expressions are frequent in patients with NSCLCs and it did not correlate with clinical stage;.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963184.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Psyrri D, Pectasides E, Weinberger P, Sasaki C, Burtness B, Fountzilas G: Outcome and molecular features of head and neck squamous cell carcinomas (HNSCC) bearing a p16 high phenotype. J Clin Oncol; 2009 May 20;27(15_suppl):6031

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome and molecular features of head and neck squamous cell carcinomas (HNSCC) bearing a p16 high phenotype.
  • : 6031 Background: We have previously demonstrated that p16 expression defines a biologically distinct subgroup of oropharyngeal squamous cell cancers (OSCC).
  • Protein expression levels for a panel of 13 markers (EGFR, MET, STAT 3, ERK 1/2, pAkt, PI3Kp85, PI3Kp110, PTEN, p53, Bcl-2, E-cadherin, β-catenin, NFκB) were analyzed using AQUA.
  • p16 positive tumors also expressed higher levels of PTEN (p = 0.0009), PI3Kp110 (p = 0.03), NFκB (p = 0.007), and Bcl-2 (p = 0.005).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962428.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Lansigan F, Cooper D, Seropian S, Foss F: Autologous and allogeneic transplantation for aggressive T-cell lymphomas: A single institution experience. J Clin Oncol; 2009 May 20;27(15_suppl):8558

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous and allogeneic transplantation for aggressive T-cell lymphomas: A single institution experience.
  • : 8558 Aggressive T-cell lymphomas (ATCL) represent 10-15% of non-Hodgkin lymphoma and have a worse prognosis than aggressive B-cell lymphomas.
  • Both autologous (Auto) and allogeneic (Allo) stem cell transplantation have been used as consolidation in first remission and at relapse, but the role of transplantation has not been clearly defined.
  • The Allo group consisted of 4 PTCLu, 3 angioimmunoblastic(AITL), 2 panniculitis-like, 2 cutaneous(CTCL) with large cell transformation, 2 NK-cell, 2 anaplastic large cell(ALCL), 1 hepatosplenic, 1 enteropathic, and 1 refractory CTCL.
  • The Auto group consisted of 6 PTCLu, 12 ALCL (5 Alk+, 5 Alk-, 2 Alk unk), 4 AITL, 1 CTCL with transformation, and 1 T-lymphoblastic lymphoma.
  • Median time from diagnosis to Allo or Auto was 18 and 8mo, respectively.
  • The non-relapse mortality was 33%(Allo) and 8%(Auto).
  • For patients with resistant or relapsed disease, Allo should be strongly considered rather than Auto.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960993.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Tawfik O, Garimella R, Tancabelic J, Keighley J, Pinson D, Khan Q, Templeton K: Retrospective immunohistochemical study of VDR, RXR, Ki-67, and Bcl-2 expression in primary and metastatic osteosarcoma. J Clin Oncol; 2009 May 20;27(15_suppl):e21516

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective immunohistochemical study of VDR, RXR, Ki-67, and Bcl-2 expression in primary and metastatic osteosarcoma.
  • : e21516 Background: Osteosarcoma (OS) is a highly malignant tumor with a peak incidence in adolescents and young adults.
  • Patient's prognosis is limited to clinical parameters whereas molecular markers of tumor aggression are yet to be identified.
  • METHODS: Immunohistochemical analysis for VDR, RXR, Ki-67, and bcl-2 was performed on 87 OS specimens to evaluate differentiation, proliferation and apoptosis.
  • Clinical data including site of the primary tumor, presence or absence of metastasis, therapeutic regimens, and outcome were recorded.
  • Thirty-five OSs were conventional, 17 chondroblastic, 6 giant cell, 6 fibroblastic, 6 mixed, 3 telangiectatic, and 2 epithelioid variants.
  • None of the tumors studied was immunoreactive for bcl-2.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963447.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Adamia S, Avet-Loiseau H, Amin SB, Moreau P, Minvielle SS, Treon S, Li C, Anderson KC, Munshi N: Clinical and biological significance of microRNA profiling in patients with myeloma. J Clin Oncol; 2009 May 20;27(15_suppl):8539

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and biological significance of microRNA profiling in patients with myeloma.
  • : 8539 MicroRNA, a small endogenous RNA regulating specific expressed gene function has been implicated in normal biological processes as well as in malignant transformation.
  • Here we have investigated the role of microRNAs in multiple myeloma (MM) biology, and their influence on prognosis and clinical outcome.
  • We evaluated profiles of 384 microRNAs in CD138+ MM cells from 79 patients with MM, 11 cell lines and 9 healthy donors using qRT-PCR based microRNA array.
  • We detected significant modulation of expression of 61 microRNAs in myeloma cells compared to normal plasma cells.
  • Group A clustered with MM cell lines, indicating more aggressive course of disease.
  • Within B group, second degree node, group B2, clustered with normal plasma cells indicating indolent course.
  • In group A miR585 and let-7f were upregulated 8-12 fold; in group B, all differentially expressed microRNAs were downregulated (p<0.001) compared to normal plasma cells.
  • These modulated miRNAs target critical signaling molecules such as HOX9, c-myc, Bcl-2, SHP1 and SHP2.
  • We further analyzed the effect of microRNA on clinical outcome.
  • Functional analysis by modulating miRNAs 585, 155 and let-7f showed change in levels of predicted genes with consequent biological effect on growth and apoptosis in MM cell line.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960934.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Nabil IN Jr, Allam W, Alaoui K, Errihani H: Primary nasopharyngeal non Hodgkin lymphoma: A retrospective investigation of 26 patients. J Clin Oncol; 2009 May 20;27(15_suppl):e19552

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary nasopharyngeal non Hodgkin lymphoma: A retrospective investigation of 26 patients.
  • : e19552 Background: Primary nasopharyngeal non-Hodgkin lymphoma (NNHL) was uncommon.
  • In this retrospective study we report our experience dealing with this disease at the National Institute of Oncology.
  • METHODS: We retrospectively analyzed various characteristics of Primary NNHL: patient demographics, clinical and histological diagnosis, disease stage, treatment effects and outcome, in 26 patients treated at our institution between January 2001 and December 2007.
  • The major symptoms at first diagnosis were: nasal obstruction (88.6%), hypoacousia (88.4%), epistaxis (33.3%) and rhinorrhea (15.3%).
  • Clinical examination founded bilateral cervical lymph nodes in 17 cases (65%).
  • Histological analysis showed follicular lymphoma in 7 cases (26.9%), large B-cell lymphoma in 11 cases (42,3%) and T lymphoma in 4 cases ( 15,3%).
  • At the end of total treatment, 18 patients (69.2%) achieved complete response and remained disease free while 4 (15.4%) achieved partial response (>70%) and 4 (15.4%) were progressive (these patients received second line chemotherapy).
  • After 110 months median flow-up, median disease free and overall survival were not reached.
  • CONCLUSIONS: From our study and from the literature, we conclude that histological characteristics, principle of treatment and outcome of primary NNHL patients are similar to that of patients with nodal lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961093.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Ready N, Potti A, Karaseva N, Orlov S, Luft A, Popovych O, Liu PY, Holmlund JT, Wood BA, Leopold L: AT-101 or placebo (P) with docetaxel (D) in second-line NSCLC with gene signature biomarker development. J Clin Oncol; 2009 May 20;27(15_suppl):3577

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 3577 Background: AT-101 inhibits the Bcl-2 protein family (Bcl-2, Bcl-xL, Mcl-1, Bcl-W) with broad preclinical activity including synergy with D.
  • A biomarker of AT-101 activity was developed by treating 55 NSCLC cell lines with AT-101 and using the corresponding gene expression data to identify a genomic predictor of sensitivity to AT-101.
  • Analysis of gene expression data by Bayesian regression revealed a robust 500 gene predictor of sensitivity to AT-101 that was cross validated in a leave one out analysis and in an independent cohort of 32 NSCLC cell lines.
  • CONCLUSIONS: In this phase II trial AT-101, an oral pan Bcl-2 family inhibitor, had favorable OS compared to placebo when combined with docetaxel in previously treated NSCLC and was well tolerated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961708.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Kasimis B, Chang V, Gounder S, Gonzalez M, Finch-Cruz C, Blumenfrucht M, Srinivas S, Cogswell J, Morales E, Ahmed S: Prediction of survival by immunohistochemical stains (IHC) in stage D2 prostate cancer patients (pts): The importance of pTEN overexpression. J Clin Oncol; 2009 May 20;27(15_suppl):e16019

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All pts has androgen deprivation for stage D2 disease and were followed at 3 month intervals.
  • METHODS: In an IRB approved study,42 pts had adequate tissue preserved between 1992 and 2006 and their charts were reviewed retrospectively.IHC stains to detect tumor expression of S6(ribosomal),p70s6,pTEN,AKT-1,BCL-1(Cyclin D1),VEGF,c-KIT,PDGFR-alpha and PDGFR-beta were performed by US Labs(Irvine,CA).All results were independently evaluated by two pathologists.Immunoreactivity was scored using a semiquantitative system combining intensity of staining(0-3+) and percentage of cells staining positive(0-3+).The total score was obtained by adding the scores for indensity and the percentage of positive cells,then averaging the resuts obtained by each reader.For the purpose of this study, stain intensity of 0-1+ was considered negative and the intensity of 2-3+ was considered positive.A Cox regression survival model for each stain was developed with variables known to predict survival :Gleason score,Hemoglobin(Hgb),Alkaline Phosphatase(Alk Phos),Prostate Specific Antigen(PSA),Lactate Dehydrogenase(LDH) levels.
  • CONCLUSIONS: In this small sample of pts, overexpression of S6,p70s6,AKT-1,BCL-1,VEGF,c-KIT,PDGFR-alpha and PDGFR-beta by IHC staining did not predict survival independently.The pTEN staining,however was strong predictor of survival in the multivariate analysis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962908.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. De La Mota J, Thomas B, Fengwei W, Micaily B, Yajue H, Hernandez E: Surgical and immunohistochemical (IC) risk factors for metastatic disease in stage IB1 cervical cancer (CC). J Clin Oncol; 2009 May 20;27(15_suppl):e16578

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical and immunohistochemical (IC) risk factors for metastatic disease in stage IB1 cervical cancer (CC).
  • We sought to identify surgical and IC risk factors for metastatic disease.
  • RESULTS: Of the 35 patients identified, 25 (71%) had squamous cell, 9 (26%) adenocarcinoma, and 1 (3%) adenosquamous histology.
  • Immunohistochemical (IC) staining was performed on 29 cases (10 LVI, 4 positive LN) for bcl-2, p53, Ki-67.
  • No correlation was found with p53 or Bcl-2.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961498.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Vose J, Loberiza F, Armitage J, Bierman P, Bociek R, Dornan D: Effects of FCGR3A and FCGR2A polymorphisms on outcomes of patients with diffuse large B-cell lymphoma treated with CHOP-like chemotherapy versus CHOP-rituximab. J Clin Oncol; 2009 May 20;27(15_suppl):8567

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of FCGR3A and FCGR2A polymorphisms on outcomes of patients with diffuse large B-cell lymphoma treated with CHOP-like chemotherapy versus CHOP-rituximab.
  • : 8567 Background: The addition of rituximab to cyclophosphamide/ doxorubicin/ vincristine/ prednisone (R-CHOP) therapy for diffuse large B-cell lymphoma (DLBCL) has significantly improved the outcome for many patients (pts).
  • In a multivariate analysis for risk of progression or death: FCGR2A : H/H vs. H/R or R/R by treatment type: CHOP-like [RR 0.63 (95% CI 0.37-1.08), p=0.10] and R-CHOP [RR 0.59 (0.36-0.96), p=0.04] and for FCGR3A V/V vs. F/V or F/F by treatment arm: CHOP-like [RR 0.75 (0.36-1.54), p=0.43] and R-CHOP [RR 2.28(0.70-7.44), p=0.17].
  • However, our study also suggests that a trend toward association of certain polymorphisms with clinical outcomes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961024.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Gerrard M, Waxman I, Sposto R, Auperin A, Harrison L, Pinkerton R, Perkins SL, McCarthy K, Raphael M, Patte C, Cairo MS, FAB/LMB 96 Trial: Association of primary mediastinal B-cell lymphoma (PMBL) in children (C) and adolescents (A) with a significantly inferior prognosis: Final results of the FAB/LMB 96 trial. J Clin Oncol; 2009 May 20;27(15_suppl):10001

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of primary mediastinal B-cell lymphoma (PMBL) in children (C) and adolescents (A) with a significantly inferior prognosis: Final results of the FAB/LMB 96 trial.
  • : 10001 Background: Single pediatric cooperative group studies have demonstrated an EFS ranging from 65 - 75% in C & A with large cell lymphomas arising in the mediastinum (Lones/Cairo et al, J Clin Oncol, 2000; Burkhardt/Reiter et al, Br J Haematol, 2005; Seidman/Reiter et al, J Clin Oncol, 2003).
  • Recently, Staudt and Shipp have independently demonstrated that following gene expression profiling by oligonucleotide microarray that PMBL resembles more like classical Hodgkin lymphoma than diffuse large B-cell lymphoma with enhanced NF-κB pathway gene expression (Rosenwald et al, J Exp Med, 2003; Abramson et al, Blood, 2005).
  • RESULTS: There were 528 patients with stage III/IV disease treated on group B therapy on FAB/LMB 96 resulting in a 2 yr EFS of 84% (CI<sub>95</sub>: 82-86%).
  • 5 yr EFS was significantly inferior compared to the remainder of the other patients with stage III disease treated on group B therapy (54%: CI<sub>95</sub> 38-68% vs 85%: CI<sub>95</sub> 81-88%) (p < 0.001).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962546.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Gratzinger D, Advani R, Zhao S, Talreja N, Tibshirani RJ, Horning SJ, Levy R, Lossos IS, Gascoyne RD, Natkunam Y: Prognostic significance of vascular endothelial growth factor (VEGF), VEGF receptors (VEGFR), and vascularity in diffuse large B-cell lymphoma treated with immunochemotherapy (R-CHOP). J Clin Oncol; 2009 May 20;27(15_suppl):8581

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of vascular endothelial growth factor (VEGF), VEGF receptors (VEGFR), and vascularity in diffuse large B-cell lymphoma treated with immunochemotherapy (R-CHOP).
  • : 8581 Background: Diffuse large B cell lymphoma (DLBCL) cells coexpress VEGF, VEGFR1 and VEGFR2.
  • METHODS: 162 pts with de novo DLBCL treated with R-CHOP and median followup of 44 months were evaluated retrospectively with immunohistochemistry on tissue microarrays.
  • Scoring: VEGF, VEGFR1, VEGFR2, and phosphoVEGFR2 (pVEGFR2) in lymphoma cells (categorical variable) <5%, none; 5-30%, weak; >30%, strong.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962266.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Yoo C, Sohn B, Kim J, Yoon D, Huh J, Kim S, Lee D, Kim S, Lee J, Suh C: The prognostic significance of the number of extranodal sites in the patients with disseminated diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol; 2009 May 20;27(15_suppl):8570

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognostic significance of the number of extranodal sites in the patients with disseminated diffuse large B-cell lymphoma treated with R-CHOP.
  • : 8570 Background: The combination of rituximab and CHOP chemotherapy (R-CHOP) has improved survival of patients with diffuse large B-cell lymphoma (DLBCL).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961016.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Gisselbrecht C, Glass B, Mounier N, Gill D, Linch D, Trneny M, Bosly A, Shpilberg O, Ketterer N, Moskowitz C, Schmitz N: R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study. J Clin Oncol; 2009 May 20;27(15_suppl):8509

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study.
  • : 8509 Background: Salvage chemotherapy followed by high dose therapy and autologous stem cell transplantation (ASCT) is the standard of treatment for chemosensitive relapses in diffuse large B cell lymphoma.
  • Patients with prior exposure to rituximab had more refractory disease and adverse prognostic factors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960863.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Yi J, Kim S, Lee S, Park S, Ko Y, Choi J, Kim W: Clinical usefulness of PET/CT in initial staging and response evaluation of primary gastric lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):e19541

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical usefulness of PET/CT in initial staging and response evaluation of primary gastric lymphoma.
  • : e19541 Background: Positron emission tomography (PET)/computed tomography (CT) scan has a well-established role in the management of non-Hodgkin's lymphoma (NHL).
  • However, in case of the primary gastric lymphoma, which is the most frequent extranodal NHL, the role of PET/CT scan is still controversial.
  • METHODS: We retrospectively analyzed 42 patients with primary gastric lymphoma who underwent PET/CT scans; 32 patients with diffuse large B-cell lymphoma (DLBCL) and 10 patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) were analyzed.
  • After corresponding treatment, response was evaluated by conventional CT scans or PET/CT scans and endoscopy with biopsy Results: Nine patients were up-staged based on the results of their PET/CT scan compared to CT (7 DLBCL, 2 MALT lymphomas) while six patients were down-staged by the PET/CT scan.
  • Three patients with DLBCL, who showed an initially high SUVmax, died of disease progression.
  • All of these gastric lesions were grossly and pathologically benign lesions without evidence of lymphoma cells.
  • CONCLUSIONS: PET/CT scan can help staging patients with primary gastric lymphoma, and the maximum SUV has possibility to have prognostic value.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960998.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Momota H, Narita Y, Miyakita Y, Shinomiya A, Maeshima A, Maruyama T, Muragaki Y, Shibui S: Expression and prognostic significance of differentiation markers in primary CNS lymphoma (PCNSL). J Clin Oncol; 2009 May 20;27(15_suppl):e13028

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and prognostic significance of differentiation markers in primary CNS lymphoma (PCNSL).
  • : e13028 Background: BCL-6 expression has been reported to be associated with a better prognosis in PCNSL.
  • However, significant differences of B-cell lymphoma subtypes exist in different geographic regions.
  • The objectives of this study were to characterize the immunophenotypes of PCNSL in Japan and to determine their utility in predicting clinical outcomes.
  • METHODS: Immunostaining for CD5, CD10, BCL-6, and MUM-1 was done to determine the profile of diffuse large B-cell lymphoma of PCNSL from 27 immunocompetent patients in Japan.
  • Then, the authors evaluated whether clinical and immunophenotypic markers were associated with progression-free or overall survival.
  • RESULTS: Germinal center B-cell (GCB) marker CD10 was positive in 22% of PCNSL samples, while another GCB marker BCL-6 was positive in 48% of samples.
  • Poor prognostic marker of systemic B-cell lymphoma CD5 was expressed in 15% of samples.
  • In univariate analyses, only BCL-6 expression had a significant effect on progression-free survival (median, 6.1 months in BCL-6-positive patients versus 15.6 months in BCL-6-negative patients; p = 0.037).
  • Patients with BCL-6 expression had a trend towards longer overall survival but nonsignificant.
  • GCB subgroup (CD10-positive or CD10-negative/BCL-6-positive/MUM-1-negative) was not significantly associated with favorable survival.
  • CONCLUSIONS: BCL-6 expression is associated with a poor prognosis in patients with PCNSL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962799.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Matous J, Letzer J, Rosen P, Noga S, Fowler N, Smith S, Amin B, Shi H, Parasuraman S, Cheson B: Bortezomib, bendamustine, and rituximab in patients (pts) with relapsed (rel) or refractory (ref) follicular lymphoma (FL): Dose-finding results of the VERTICAL study. J Clin Oncol; 2009 May 20;27(15_suppl):8550

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bortezomib, bendamustine, and rituximab in patients (pts) with relapsed (rel) or refractory (ref) follicular lymphoma (FL): Dose-finding results of the VERTICAL study.
  • : 8550 Background: FL is an incurable indolent B-cell non-Hodgkin's lymphoma.
  • Bortezomib (Velcade, V) plus R was active and generally well tolerated in rel/ref FL [de Vos ASH 2006 Abs694], and bendamustine hydrochloride (Treanda, B) plus R has also shown activity in heavily pretreated FL [Robinson JCO 2008].
  • METHODS: Pts with relapsed FL with ≥4 prior doses of R (no prior V or B), ≥1 measurable tumor mass, no active central nervous system lymphoma, KPS ≥50%, adequate hematologic, renal and hepatic function, and no peripheral neuropathy ≥G2 were eligible.
  • B dose escalation continued based on cycle 1 dose-limiting toxicities (DLTs), defined as: treatment-related platelet count <25,000/mm<sup>3</sup> for >7 days or any platelet count <10,000/mm<sup>3</sup>; G4 neutropenia for >7 days; any treatment-related ≥G3 non-hematologic toxicity other than inadequately treated nausea, vomiting, or diarrhea; or any toxicity resulting in >1 week treatment delay.
  • RESULTS: Sixteen pts (4 at B 50 mg/m<sup>2</sup>, 6 each at B 70 and 90 mg/m<sup>2</sup>) with a median of 3 prior therapies (range 1-13; 31% prior stem-cell transplantation) have been treated (15 evaluable for DLT); median age was 54.5 (44-80) yrs.
  • Non-hematologic AEs ≥G3 in >1 pt were diarrhea (31%), fatigue (25%), vomiting (13%), and nausea (13%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960956.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Heist RS, Fain J, Chinnasami B, Khan W, Molina J, Brainerd V, Leopold L, Lynch T: A phase I/II (P1/P2) study of AT-101 in combination with topotecan (T) in patients with relapsed or refractory small cell lung cancer (SCLC) after prior platinum-containing first-line chemotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):8106

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I/II (P1/P2) study of AT-101 in combination with topotecan (T) in patients with relapsed or refractory small cell lung cancer (SCLC) after prior platinum-containing first-line chemotherapy.
  • : 8106 Background: Bcl-2 family proteins are expressed in SCLC and are associated with chemotherapy resistance.
  • AT-101 is an oral, pan Bcl-2 family protein inhibitor (Bcl-2, Bcl-X<sub>L</sub>, Mcl-1, and Bcl-w) and potent inducer of proapoptotic proteins.
  • AT-101 has demonstrated activity in SCLC models, including those that express Mcl-1 and are resistant to other Bcl-2 inhibitors.
  • METHODS: Pts ≥18 years of age, PS 0-1, with relapsed or refractory SCLC after first line chemotherapy with measurable disease per RECIST were eligible.
  • The PR/SD/PD/NE rates were 17%/70%/9%/4% and 8%/54%/23%/15%, in cohorts A/B respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964282.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Naqi N, Khatak J: Neutrophil toxicity and primary prophylaxis in diffuse large B cell lymphoma treated with R-CHOP. J Clin Oncol; 2009 May 20;27(15_suppl):e19548

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neutrophil toxicity and primary prophylaxis in diffuse large B cell lymphoma treated with R-CHOP.
  • : e19548 Background: Three weekly R-CHOP therapy is regarded as standard treatment in advanced stage Diffuse Large B Cell Lymphoma (DLBCL) patients with low to intermediate-risk International prognostic index (IPI).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960978.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Guan Y, Ramasamy Reddy K, Zhu Q, Li Y, Lee K, Weerasinghe P, Prchal J, Semenza GL, Jing N: G-rich Oligonucleotides Inhibit HIF-1α and HIF-2α and Block Tumor Growth. Mol Ther; 2010 Jan;18(1):188-197

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : Hypoxia-inducible factor-1 (HIF-1) plays crucial roles in tumor promotion by upregulating its target genes, which are involved in energy metabolism, angiogenesis, cell survival, invasion, metastasis, and drug resistance.
  • The lead compounds, JG243 and JG244, which form an intramolecular parallel G-quartet structure, selectively target HIF-1α and decreased levels of both HIF-1α and HIF-2α (IC<sub>50</sub> < 2 µmol/l) and also inhibited the expression of HIF-1-regulated proteins [vascular endothelial growth factor (VEGF), Bcl-2, and Bcl-X<sub>L</sub>], but did not disrupt the expression of p300, Stat3, or p53.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 The American Society of Gene & Cell Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28178550.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Samuel S, Tumilasci VF, Oliere S, Liên-Anh Nguyên T, Shamy A, Bell J, Hiscott J: VSV Oncolysis in Combination With the BCL-2 Inhibitor Obatoclax Overcomes Apoptosis Resistance in Chronic Lymphocytic Leukemia. Mol Ther; 2010 Dec;18(12):2094-2103

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] VSV Oncolysis in Combination With the BCL-2 Inhibitor Obatoclax Overcomes Apoptosis Resistance in Chronic Lymphocytic Leukemia.
  • In chronic lymphocytic leukemia (CLL), overexpression of antiapoptotic B-cell leukemia/lymphoma 2 (BCL-2) family members contributes to leukemogenesis by interfering with apoptosis; BCL-2 expression also impairs vesicular stomatitis virus (VSV)-mediated oncolysis of primary CLL cells.
  • In the effort to reverse resistance to VSV-mediated oncolysis, we combined VSV with obatoclax (GX15-070)'a small-molecule BCL-2 inhibitor currently in phase 2 clinical trials'and examined the molecular mechanisms governing the in vitro and in vivo antitumor efficiency of combining the two agents.
  • In combination with VSV, obatoclax synergistically induced cell death in primary CLL samples and reduced tumor growth in severe combined immunodeficient (SCID) mice-bearing A20 lymphoma tumors.
  • Combination treatment triggered the release of BAX from BCL-2 and myeloid cell leukemia-1 (MCL-1) from BAK, whereas VSV infection induced NOXA expression and increased the formation of a novel BAX-NOXA heterodimer.
  • These studies offer insight into the synergy between small-molecule BCL-2 inhibitors such as obatoclax and VSV as a combination strategy to overcome apoptosis resistance in CLL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 The American Society of Gene & Cell Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28160637.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Karimi P, Shokri A, Etemadi L, Negar Rezania N: Factors affecting the hematological and nonhematological toxicities in B-cell lymphoma patients during treatment. J Clin Oncol; 2009 May 20;27(15_suppl):e18004

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors affecting the hematological and nonhematological toxicities in B-cell lymphoma patients during treatment.
  • : e18004 Background: Despite recent improvements, toxicities in B-cell lymphoma patients during treatment remains a major challenge for leukemia community.
  • The aim of this study was to determine factors affecting the hematological and non-hematological toxicities in B-cell lymphoma patients during treatment.
  • METHODS: This multicentral cross-sectional study was performed on 68 diagnosed B-cell lymphoma patients (17-72 y/o, mean age 53y/o) admitted in three cancer centers for treatment during 2003-2008.
  • Demographic data, clinical and para clinical manifestations were recorded during treatment.
  • RESULTS: 31 (45%) patients developed grade 2 or greater non-hematological toxicities: 11:fever, 8:chills, 6:vomiting, 4:rash, and 3:pruritus.
  • Moreover, 7 patients developed grade 3 non-hematological toxicities.
  • Non-hematological toxicities were more frequent in patients with BM (Bone Marrow) involvement [15/32 (47%) versus 21/60 (35%), p = 0.01] and with extranodal disease [23/48 (48%) versus 11/42 (26%), p = 0.008].
  • CONCLUSIONS: Multivariate analysis demonstrate that some factors like female gender, BM involvement, and serum LDH level could be useful for predicting the hematological and nonhematological toxicities in B-cell lymphoma patients during treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964008.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Johnston PB, LaPlant B, Kurtin P, Habermann T, Moore D, Nabbout N, Nikcevich D, Rowland K, Witzig T: Salvage chemotherapy with rituximab, oxaliplatin, cytosine arabinoside, and dexamethasone (ROAD) in patients with relapsed CD20+ aggressive B-cell lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):8556

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage chemotherapy with rituximab, oxaliplatin, cytosine arabinoside, and dexamethasone (ROAD) in patients with relapsed CD20+ aggressive B-cell lymphoma.
  • : 8556 Background: In the original PARMA trial it was demonstrated that salvage chemotherapy with DHAP followed by autologous bone marrow transplant resulted in increased overall survival over salvage chemotherapy with DHAP alone in patients with aggressive lymphomas.
  • Patients were considered for autologous stem cell transplantation after 2 cycles if eligible.
  • Eligible histologies included diffuse large B cell lymphoma, mantle cell lymphoma and transformed lymphoma in first relapse.
  • 31 patients experienced grade III/IV hematologic toxicity and 22 patients had grade III/IV non-hematologic toxicity, primarily febrile neutropenia.
  • One patient developed grade III nephrotoxicity due to disease progression.
  • CONCLUSIONS: ROAD is a safe and effective salvage chemotherapy regimen for relapsed aggressive lymphoma, including as a preparatory regimen prior to stem cell transplant.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960991.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Miyazaki K, Yamaguchi M, Suzuki R, Niitsu N, Ennishi D, Tamaru J, Kagami Y, Katayama N, Kinoshita T, Nakamura S: Retrospective analysis of CD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL) treated with chemotherapy with or without rituximab. J Clin Oncol; 2009 May 20;27(15_suppl):8551

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective analysis of CD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL) treated with chemotherapy with or without rituximab.
  • Intravascular large B-cell lymphoma, primary CNS DLBCL, and secondary CD5+ DLBCL were excluded from the study population.
  • RESULTS: 313 pts showed the following clinical features: median age, 67 (range: 15-93); M:F=163:150; elevated serum LDH level, 71%; stage III/IV, 64%; IPI HI/H, 53%.
  • No significant difference in clinical background such as the IPI and its five components, B symptom, male sex, and bone marrow involvement was found between pts who were treated with and without rituximab.
  • 16 of the 20 pts (80%) with CNS relapse in the rituximab group had brain parenchymal disease.
  • Future prospective studies to decrease CNS disease for CD5+ DLBCL are warranted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960955.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Min P, Zhang Y, Ni X, Wang H, Wang J, Wang G, Leopold L, Sorensen M, Yang D: Small molecule pan-bcl-2 inhibitor AT-101 induces apoptosis in NSCLC by up-regulating noxa and enhances antitumor activity of docetaxel or targeted kinase inhibitors. J Clin Oncol; 2009 May 20;27(15_suppl):e14591

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small molecule pan-bcl-2 inhibitor AT-101 induces apoptosis in NSCLC by up-regulating noxa and enhances antitumor activity of docetaxel or targeted kinase inhibitors.
  • : e14591 Background: AT-101 is an orally active pan Bcl-2 inhibitor currently under clinical development in Phase II trials.
  • RESULTS: A panel of 11 NSCLC cell lines with overexpression of Bcl-2, Bcl- X<sub>L</sub> or Mcl-1 proteins was treated with AT-101, docetaxel, pemetrexed, erlotinib, sorafenib, sunitinib, rapamycin, as a single agent and in combination.
  • When treating cells simultaneously with both agents, AT-101 demonstrated strong synergy with those agents in A549 or H460 cells with CI values < 1.0.
  • Protein analysis results indicated that AT-101 caused apoptosis by a time- and dose-dependent induction of Noxa expression in those cells.
  • The expression of Bcl- X<sub>L</sub> was not influenced by AT-101.
  • In vivo, combined treatment of AT-101 with docetaxel, erlotinib, or sorafenib synergistically suppressed subcutaneous NSCLC A549 cells tumor growth compared with treatment with either agent alone.
  • The synergist effects with the ErbB1 inhibitor Erlotinib is associated with the overexpression of the target protein ErbB1 in those cells.
  • Molecular targeted therapy with AT-101 may improve the outcome of current chemotherapy for NSCLC with Bcl-2, Bcl-xL and/or Mcl-1 overexpression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963737.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Zhang M, Huck J, Hyer M, Ecsedy J, Manfredi M: Effect of Aurora A kinase inhibitor MLN8237 combined with rituximab on antitumor activity in preclinical B-cell non-Hodgkin's lymphoma models. J Clin Oncol; 2009 May 20;27(15_suppl):8553

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of Aurora A kinase inhibitor MLN8237 combined with rituximab on antitumor activity in preclinical B-cell non-Hodgkin's lymphoma models.
  • : 8553 Background: Aurora A kinase is a serine/threonine protein kinase that is essential for the successful transit of cells through mitosis.
  • In this study we explored the anti-tumor effect of MLN8237 in vivo in pre-clinical models of human Diffuse Large B-cell Lymphoma (DLBCL) both as a single agent and in combination with the anti-CD20 monoclonal antibody Rituximab.
  • In two of the models (Ly19 & WSU) the tumor cells expressed a constitutively active luciferase, enabling tumor burden analysis in either a subcutaneous or disseminated setting.
  • In the primary lymphoma model, MLN8237(10-20mg/kg) caused a significant anti-tumor effect during treatment period (TGI = 83-95%).
  • MLN8237 is currently being tested as a single agent in a phase I clinical trail in patients with DLBCL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960986.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Nagai H, Kusumoto S, Sawada K, Yamaguchi M, Takayama N, Kinoshita T, Motoji T, Omachi K, Ogura M, Hotta T: Phase II study of cladribine with rituximab (R-2-CdA) therapy in patients with relapsed indolent B-cell non-Hodgkin's lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):e19501

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of cladribine with rituximab (R-2-CdA) therapy in patients with relapsed indolent B-cell non-Hodgkin's lymphoma.
  • : e19501 Background: Although cladribine has been reported to be one of active purine analogs against indolent B-cell non-Hodgkin's lymphoma (B-NHL), there are few reports of combination usage of cladribine and rituximab.
  • Histologies included 16 follicular lymphomas, 2 MALT lymphomas, 1 nodal marginal B cell lymphoma, and 1 lymphoplasmacytic lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960885.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Timmerman J, Betting D, Yamada R, Hurvitz S, Steward K, Said J, van Rooijen N, Kafi K: In vivo activity of rituximab-CpG oligodeoxynucleotide conjugate against rituximab-resistant human CD20+ B-cell lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):8529

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo activity of rituximab-CpG oligodeoxynucleotide conjugate against rituximab-resistant human CD20+ B-cell lymphoma.
  • : 8529 Background: The anti-CD20 monoclonal antibody rituximab (R) is a mainstay in the treatment of B cell non-Hodgkin's lymphoma (NHL), exerting anti-tumor effects via antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity, and apoptosis induction.
  • Toll-like receptor 9 agonist CpG oligodeoxynucleotides (CpG) are potent activators of ADCC and T cell immunity, and have been studied for anti-NHL effects when administered by systemic or intratumoral routes.
  • METHODS: We utilized an aggressive syngeneic human CD20-expressing murine B cell lymphoma (38C13-huCD20) to study the in vivo augmentation of R efficacy by CpG.
  • Mechanistic studies indicated that both natural killer cells and complement participated in the cure of tumors by intratumoral CpG + R, by increasing tumor cell sensitivity to complement and ADCC lysis, and by augmenting the cytotoxicity of ADCC effectors.
  • To overcome the need for repeated direct intratumoral injections and allow precise targeting of CpG to tumor cells, we chemically linked CpG to R using a cleavable linker.
  • R-CpG conjugate efficiently eradicated an established B cell lymphoma that is fully resistant to single-agent R.
  • Clinical testing of anti-CD20-CpG conjugates against B cell NHL is thus warranted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960908.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Weyl Ben Arush M Sr, Hersalis Eldar A, Abrahami G, Attias D, Ben Barak A, Dvir R, Gabriel H, Kapelushnik J, Kaplinsky H, Vilk-Revel S: Burkitt lymphoma in children: The Israel Society of Pediatric Hematology Oncology retrospective study. J Clin Oncol; 2009 May 20;27(15_suppl):10051

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt lymphoma in children: The Israel Society of Pediatric Hematology Oncology retrospective study.
  • : 10051 Background: From 2000 to 2005, the Israel Society of Pediatric Hematology Oncology studied the results of the FAB-LMB 96 protocol in children with B cell lymphoma.
  • Fifty patients (57%) were classified as burkitt lymphoma, 5 (5.7%) as burkitt-like lymphoma, 22 (25%) as diffuse large B cell (DLBC), 9 (10.2%) as burkitt leukemia.
  • Initial disease sites included the abdomen in 43%, head and neck in 45%, mediastinum in 7%.
  • CONCLUSIONS: In nonresected mature B cell lymphoma of childhood and adolescence with no BM or CNS involvement, a 93% cure rate was achieved.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962447.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Ridolfi L, Fiammenghi L, Petrini M, Granato AM, Ancarani V, Pancisi E, Valmorri L, Riccobon A, Ridolfi R: Dendritic cell vaccination in melanoma patients: Update and subgroup analysis of clinical response to post-vaccine treatment. J Clin Oncol; 2009 May 20;27(15_suppl):9042

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dendritic cell vaccination in melanoma patients: Update and subgroup analysis of clinical response to post-vaccine treatment.
  • : 9042 Background: Dendritic cells (DCs) play a crucial role in the interplay between innate and adaptive immune response towards cancer.
  • In the literature, higher response rates than those normally obtained have been reported after second-line chemotherapy in patients with non small cell lung cancer pre-treated with vaccines and in patients with follicular B-cell lymphoma vaccinated with an anti-idiotype vaccine whilst in remission.
  • On the basis of this data, we reviewed and updated the clinical results of our dendritic cell based vaccine clinical trial in stage IV melanoma patients.
  • RESULTS: We observed 2 complete response (CR), 2 mixed response (MR), 5 partial response (PR), 4 stable disease (SD) and 11 progressive disease (PD) (overall response (OS) 37.5%; clinical benefit 54.1%).
  • All 13 responders had delayed-type hypersensitivity (DTH) positivity to KLH, of whom 10 also showed positivity to the lysate.
  • Vaccination could enhance clinical response to subsequent third- or fourth-line therapies, thus prolonging overall survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962107.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Azim HA, Malek RA, Santoro L, Gandini S, Bociek RG, Azim HA Jr: High-dose intense doxorubicin-based regimens in aggressive non-Hodgkin's lymphoma: A systematic overview. J Clin Oncol; 2009 May 20;27(15_suppl):e19528

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose intense doxorubicin-based regimens in aggressive non-Hodgkin's lymphoma: A systematic overview.
  • : e19528 Background: Aggressive non-Hodgkin's lymphoma represents around 60% of lymphomas in the Western world and even more in Egypt.
  • CHOP has been long been recognized as the standard chemotherapy regimen in this disease.
  • The addition of rituximab (R) to CHOP in the treatment of B-cell subtypes has resulted in a significant improvement in all treatment endpoints.
  • Thus CHOP is still offered to these patients as well as those with T-cell subtypes.
  • METHODS: A MEDLINE and COCHRANE library search was performed using the search terms 'CHOP', 'lymphoma' and 'randomized trials'.
  • Such approach should be considered in patients with aggressive B-cell lymphomas not offered R as well as those with T-cell lymphomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960914.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Tay K, Shapiro G, Disinski M, Chirieac LR, Pittaluga S, Jaffe ES, Janik JE, Wiestner A, Wilson WH, Dunleavy K: Phase I/II study of a hybrid schedule of flavopiridol in relapsed/refractory mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL). J Clin Oncol; 2009 May 20;27(15_suppl):8563

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II study of a hybrid schedule of flavopiridol in relapsed/refractory mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL).
  • Because flavopiridol decreases cyclin D1 and mcl-1 and induces apoptosis in MCL cells, is significantly toxic for cell lines derived from the activated B-cell-like type of DLBCL (OCI-Ly3) and down-regulates NF-kappa B, we investigated the hybrid schedule in MCL and DLBCL.
  • Analysis of cell cycle and transcriptional cdk targets is ongoing.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961020.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Czuczman MS, Vose J, Zinzani P, Reeder C, Buckstein R, Haioun C, Bouabdallah R, Polikoff J, Ervin-Haynes A, Witzig T: Efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma: Results from an international study (NHL-003). J Clin Oncol; 2009 May 20;27(15_suppl):e19504

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma: Results from an international study (NHL-003).
  • : e19504 Background: Patients with diffuse large-B-cell lymphoma (DLBCL) who are not cured with R-CHOP or high-dose chemotherapy with autologous stem cell rescue have a dismal prognosis.
  • A recent phase II trial (NHL-002) of lenalidomide in patients with relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL) demonstrated a 19% overall response rate (ORR) with a 7-month median duration of response (DR) in the subset of patients with DLBCL.
  • A supporting international phase II trial (NHL-003) of single-agent lenalidomide was initiated for patients with relapsed or refractory aggressive NHL that had received at least one prior treatment and had measurable disease.
  • METHODS: Patients received 25 mg oral lenalidomide once daily on days 1-21 of every 28-day cycle and continued therapy until disease progression or toxicity.
  • Median time from diagnosis was 2 years (0.4-18.6), patients had received a median of 3 prior treatment regimens (1-10) and 46 of the patients (45%) had received a prior stem cell transplant (DLBCL-stem cell).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960873.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Larouche J, Berger F, Chassagne-Clement C, Sebban C, Ghesquieres H, Salles G, Coiffier B: Lymphoma recurrence 5 years or more following diffuse large B-cell lymphoma: Clinical characteristics and outcome. J Clin Oncol; 2009 May 20;27(15_suppl):8562

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoma recurrence 5 years or more following diffuse large B-cell lymphoma: Clinical characteristics and outcome.
  • : 8562 Background: Diffuse large B-cell lymphoma (DLBCL) usually relapses early following treatment but some relapses happen 5 years or later.
  • Few data exist regarding clinical characteristics and outcome of these patients (pts).
  • METHODS: We performed a retrospective analysis of all pts from two centers in Lyon/France between 1980-2003 who presented a biopsy proven relapse 5 years or later following diagnosis of DLBCL.
  • Clinical characteristics at diagnosis were: median age 57 y; stage I-II 63% (34/54); IPI low/low intermediate 84% (41/49) and extranodal involvement (EN) 66% (35/53).
  • IHC at diagnosis: CD20 100% (46/46), CD10 28% (10/36), bcl-6 53% (9/17), MUM1 48% (11/23), bcl-2 68% (19/28), germinal-center phenotype (GC) 57% (12/21) and non-GC 43% (9/21).
  • Median time from diagnosis to relapse was 7.4 years (5-20.5 years).
  • MUM1 expression at diagnosis was associated with DLBCL histology at relapse (p=0.037).
  • Clinical characteristics at relapse were: median age 66 y; stage I-II 48% (26/54); 73% (31/43) with DLBCL at relapse had EN.
  • 54% (15/28) with DLBCL at relapse had a GC phenotype and 46% (13/28) a non-GC phenotype.
  • CONCLUSIONS: Patients with DLBCL who present a late relapse usually had localized stage, favorable IPI and extranodal involvement at diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960984.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Duvic M, Forero-Torres A, Foss F, Olsen E, Pinter-Brown L, Kim Y: Long-term treatment of CTCL with the oral PNP inhibitor, forodesine. J Clin Oncol; 2009 May 20;27(15_suppl):8552

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 8552 Background: Forodesine is a potent inhibitor of purine nucleoside phosphorylase (PNP) that leads to T-cell selective intracellular accumulation of dGTP, resulting in apoptosis.
  • Additional subjects were accrued at an OBD (80 mg/m<sup>2</sup>) to further assess safety and clinical efficacy.
  • Six discontinued treatment (median time on treatment 440 days): 4 for progressive disease, 1 withdrew consent, and 1 due to an adverse event (Diffuse Large B-cell Lymphoma).
  • Five of 9 subjects had a response (2 with complete response, 3 with partial response, and 4 with stable disease).
  • Grade 3 or higher related AEs were experienced by 2 of 9 subjects (Diffuse Large B-Cell Lymphoma as previously mentioned and peripheral edema).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960987.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Siegelin M: KAAD-cyclopamine sensitize malignant glioma cells to TRAIL-mediated apoptosis. J Clin Oncol; 2009 May 20;27(15_suppl):2025

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KAAD-cyclopamine sensitize malignant glioma cells to TRAIL-mediated apoptosis.
  • : 2025 Background: Malignant gliomas are the most aggressive human brain tumors without any curative treatment.
  • Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising cancer therapeutic because TRAIL induces almost selectively apoptosis in cancer cells.
  • The main obstacle in TRAIL-based therapy is that many glioblastoma cells are resistant.
  • In the present study we found that the Hedgehog inhibitor, KAAD-cyclopamine, potently sensitized primary glioma cells to TRAIL-mediated apoptosis.
  • METHODS: Established cell lines and isolated primary tumor glioblastoma cells were treated with achievable plasma concentrations of TRAIL, KAAD-cyclopamine, or the combination of both.
  • For transfection experiments primary glioma cells were electroporated with plasmids encoding the cDNA of c-FLIP and bcl-2.
  • RESULTS: We established a stable culture model for isolated primary human glioma cells.
  • In contrast to cell lines, isolated primary tumor cells from all investigated glioma patients were highly TRAIL resistant.
  • Single treatment with KAAD-cyclopamine or TRAIL does not induce cytotoxicity in malignant glioma cells.
  • However, treatment with KAAD-cyclopamine in combination with TRAIL induces rapid apoptosis in TRAIL-resistant glioma cells.
  • KAAD-cyclopamine led to an upregulation of death receptor 4 and 5 and down-regulation of bcl-2 and c-FLIP.
  • Furthermore, over-expression of both bcl-2 and c-FLIP attenuated KAAD-cyclopamine facilitated TRAIL-mediated apoptosis.
  • CONCLUSION: The widespread TRAIL resistance in primary glioma cells described here questions the therapeutic clinical benefit of TRAIL as a monotherapeutic agent.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964601.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Wang S, Jiang F, Bai L, Long JJ, Qiu S, Chen J, McEachern D: Effect of (-)-gossypol (AT-101) on transcriptional regulation of Noxa and Puma and on Mcl-1-mediated cancer cell resistance to apoptosis. J Clin Oncol; 2009 May 20;27(15_suppl):e14611

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of (-)-gossypol (AT-101) on transcriptional regulation of Noxa and Puma and on Mcl-1-mediated cancer cell resistance to apoptosis.
  • : e14611 Background: AT-101 is being evaluated in Phase II clinical trials for the treatment of human cancers and demonstrates anticancer activity as a single agent and in combination with docetaxel.
  • In this study, we have performed detailed investigations using a panel of human cancer cell lines on the mechanism of action for AT-101.
  • METHODS: A series of human breast and prostate cancer cell lines were utilized to evaluate the antitumor activity of AT-101.
  • Cell growth inhibition, cell viability and apoptosis were determined by WST assay, trypan blue assay and flow cytometry, respectively.
  • RESULTS: AT-101 induced apoptosis in both Bax/Bak-dependent and -independent manners in a variety of human cancer cell lines concomitant with increased expression of Noxa and Puma in a p53-independent manner.
  • The up-regulation of Noxa was not observed in normal primary breast epithelial cells or normal-like human breast epithelial MCF-12F cells.
  • Furthermore, AT-101 effectively overcame Mcl-1-mediated cancer cell resistance to apoptosis.
  • CONCLUSIONS: Our findings suggest that transcriptional up-regulation of pro-apoptotic Noxa and Puma contributes to the antitumor activity of AT-101, which plays a dominant role in antagonizing Mcl-1 and overcoming Mcl-1-mediated resistance to apoptosis of cancer cells.
  • AT-101 functions as an antagonist of Bcl-2, Bcl-xL and Mcl-1 through direct binding to these proteins, as well as through upregulation of Noxa and Puma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964122.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Park B, Kim W, Eom H, Kim J, Oh S, Suh C: A phase II trial of gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for patients with refractory or relapsed non-Hodgkin's lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):8559

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for patients with refractory or relapsed non-Hodgkin's lymphoma.
  • : 8559 Background: Gemcitabine combined with cisplatin has been known as an effective regimen for lymphoma treatment in salvage setting.
  • We investigated the response rate and toxicity of gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOx) for recurrent or refractory aggressive B-cell non-Hodgkin lymphoma (NHL), looking for the more effective and less toxic therapy.
  • METHODS: Patients with recurrent or refractory diffuse large B-cell NHL or mantle cell lymphoma, measurable disease, and more than one previous chemotherapy regimen were eligible.
  • Patients could then proceed to stem cell transplantation (SCT) or receive up to six treatment cycles.
  • The median age of the patients was 54 years (range, 18-75 years) and most had diffuse large-cell lymphoma.
  • CONCLUSIONS: GIDOx is an active salvage regimen in aggressive B-cell NHL and can be administered with acceptable toxicity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960992.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Rodriguez MA, Wei W, Huang X, Fisch M, Durand JB: Evaluation of brain natriuretic peptide (BNP), troponin levels, and left ventricular ejection fraction (LVEF) in older adults with diffuse large B cell lymphoma (DLBCL). J Clin Oncol; 2009 May 20;27(15_suppl):e19506

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of brain natriuretic peptide (BNP), troponin levels, and left ventricular ejection fraction (LVEF) in older adults with diffuse large B cell lymphoma (DLBCL).
  • There is a significant rise in BNP without clinical cardiac dysfunction.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960865.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Kingsley E, Richards D, Garbo L, Gersh R, Robbins G, Leopold L, Brill J, Di Bella N: An open-label, multicenter, phase II study of AT-101 in combination with rituximab (R) in patients with untreated, grade 1-2, follicular non-Hodgkin's lymphoma (FL). J Clin Oncol; 2009 May 20;27(15_suppl):8582

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An open-label, multicenter, phase II study of AT-101 in combination with rituximab (R) in patients with untreated, grade 1-2, follicular non-Hodgkin's lymphoma (FL).
  • : 8582 Background: Bcl-2 family proteins are overexpressed in the majority of patients with FL and contribute to resistance to therapy.
  • AT-101 is a pan-Bcl-2 inhibitor (Bcl-2, Bcl-XL, Bcl-W, and Mcl-1) and potent inducer of proapoptotic proteins.
  • Endpoints evaluated the response rate (RR) at week 8 (primary), overall response rate (ORR), molecular response rate (BCL-2JH rearrangement in blood and bone marrow), and safety of the combination.
  • RESULTS: 23 pts enrolled: median age 64 yrs; FLIPI 0-5: 0%/17%/65%/13%/4%; Grade 1/2: 61%/39%; bulky disease (>5cm<sup>3</sup>): 35%; stage: 1-4 4%/4%/30%/61%; bone marrow + 48%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962265.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Cunningham D, Smith P, Mouncey P, Qian W, Pocock C, Ardeshna KM, Radford J, Davies J, McMillan A, Linch D: A phase III trial comparing R-CHOP 14 and R-CHOP 21 for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin's lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):8506

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase III trial comparing R-CHOP 14 and R-CHOP 21 for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin's lymphoma.
  • : 8506 Background: The addition of rituximab to standard therapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP21) has resulted in improved survival outcomes in the treatment of diffuse large B-cell non-Hodgkin's lymphoma (DLBC NHL).
  • Patient characteristics in the R-CHOP21 and R-CHOP14 arms are; IPI score of ≥4 17%:15%, stage III/IV disease 63%:62%, B symptoms 44%:47%, bulk disease 51%:48%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960856.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Sahoo R, Babu V, Patil G, Kulkarni J, Rao S, Thakur S, Dondhalay G, Banerjee A, Kumar Bs A, Korlimarla A, Rao M R: Evaluation of p53 and BCL2 expression, mutation, and aneuploidy status on treatment response in an Indian cohort of primary Ca larynx. J Clin Oncol; 2009 May 20;27(15_suppl):e17057

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e17057 Background: Organ-sparing therapy consisting of cisplatin and 5-fluorouracil, combined with radiation for advanced head and neck squamous cell carcinoma (HNSCC) have been advocated in Ca larynx patients.
  • Clinical, sociodemographic information and response to treatment were abstracted from case records.
  • Independent samples t tests were used to determine changes in P53 over expression, BCL2 expression Ploidy status and S phase fractions in both responders and non responders.
  • RESULTS: There was a trend for increase in P53 over expression and BCL2 expression and decrease in S phase fractions in responders vs non responders.
  • Neither p53 over expression (75% of cases) and BCL<sub>2</sub> over expression (17% of cases) correlated significantly with treatment response.
  • However, BCL2 expression correlated negatively with disease stage (r = - 0.57, p = 0.02).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961818.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Dong M, Ning Z, Newman MJ, Xu J, Dou G, Cao H, Shi Y, Gingras MA, Lu X, Feng F: Phase I study of chidamide (CS055/HBI-8000), a novel histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas. J Clin Oncol; 2009 May 20;27(15_suppl):3529

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of chidamide (CS055/HBI-8000), a novel histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas.
  • : 3529 Background: Chidamide (CS055/HBI-8000) is a new benzamide type of histone deacetylase (HDAC) inhibitor with low nanomolar activity against HDAC1, 2, 3 and 10.
  • This Phase I study evaluated the safety and tolerability of chidamide in patients (pts) with advanced solid tumors and lymphomas.
  • METHODS: 31 pts with refractory or relapsed advanced solid tumors (22) and lymphomas (9) were enrolled in this study.
  • Significant induction of histone (H3) acetylation was observed in peripheral white blood cells, which lasted for 2-3 days in most pts after single dosing.
  • 4 pts with T-cell lymphomas (4/5 evaluable) and 1 pt with submandibular adenoid cystic carcinoma achieved PR, and 11 pts (2 B-cell lymphomas and 9 solid tumors) experienced SD.
  • CONCLUSIONS: Chidamide was well-tolerated in pts with advanced solid tumors and lymphomas in the tested regimens.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961317.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. MacVicar GR, Greco A, Reeves J, Maleski J, Holmlund J, Leopold L: An open-label, multicenter, phase I/II study of AT-101 in combination with docetaxel (D) and prednisone (P) in men with castrate-resistant prostate cancer (CRPC). J Clin Oncol; 2009 May 20;27(15_suppl):5062

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 5062 Background: Antiapoptotic Bcl-2 family proteins are overexpressed in CRPC and contribute to resistance to therapy.
  • The oral pan-Bcl-2 inhibitor AT-101 (Bcl-2, Bcl-X<sub>L,</sub> Bcl-W, Mcl-1) is active as a single agent and in combination in in vitro and in vivo tumor models and as a single agent in CRPC.
  • Radiological assessments were performed at 6-wk intervals for pts with soft tissue disease and bone scans were performed after cycle 6 and at the completion of therapy.
  • Nine of 19 pts (47%) with measurable disease had a PR.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962977.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Friedman DR, Dupont AH, Coan AD, Herndon JE 2nd, Rowe KL, Abernethy AP: Survivorship care planning needs in diffuse large B-cell lymphoma (DLBCL). J Clin Oncol; 2009 May 20;27(15_suppl):e20703

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survivorship care planning needs in diffuse large B-cell lymphoma (DLBCL).
  • Through the tumor registry, 178 patients were identified who had been treated with curative intent (including stem cell transplant) without evidence of recurrence since 1/2006 and who continue to receive care at Duke University Medical Center.
  • Responders: 58% female, 88% white, and 75% from North Carolina, with mean age at diagnosis of 59.7 years; 42% had stage four disease at diagnosis and 12% had had a transplant.
  • Other top scoring issues (mean 8.81 - 9.48) related to cancer history (treatment, complications, stage or late effects) and non-cancer health monitoring.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961990.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Cheson BD, Vose JM, Bartlett NL, Lopez A, Van der Jagt RH, Tolcher AW, Weisenburger DD, Seiz AL, Shamsili S, Keating AT: Safety and efficacy of YM155 in diffuse large B-cell lymphoma (DLBCL). J Clin Oncol; 2009 May 20;27(15_suppl):8502

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and efficacy of YM155 in diffuse large B-cell lymphoma (DLBCL).
  • : 8502 Background: Survivin is a member of the inhibitor of apoptosis proteins (IAPs) family which is responsible for preservation of cell viability and regulation of mitosis in tumor cells.
  • YM155, a survivin suppressant, has exhibited anti-tumor activity in solid tumors and non-Hodgkins lymphoma (NHL), including DLBCL patients enrolled in Phase I and Phase II monotherapy studies.
  • Patients could continue to receive YM155 until disease progression or unacceptable toxicity.
  • Two responders were refractory to their last regimen and one had relapsed approximately 2 years after stem cell transplant (SCT).
  • One patient responded after 2 cycles, completed 5 total cycles and proceeded to SCT (disease-free > 3.7 years post SCT).
  • The third patient responded after 12 cycles and received 26 total cycles (1.5 years) before disease progression.
  • Because of single-agent activity and preliminary data showing synergism when YM155 is combined with other agents additional clinical studies are being planned.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960852.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Joshi MM, Seligmann B, Sabalos C, Harpole DH Jr: Measurement of gene expression biomarkers by qNPA from archived NSCLC FFPE: Prognosis of 5-year survival. J Clin Oncol; 2009 May 20;27(15_suppl):11098

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, a method for measuring gene expression from FFPE using the quantitative Nuclease Protection Assay (qNPA) has been published in a model of diffuse large B-cell lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963124.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Bose P, Thompson CL, Gandhi DG, Ghabach BS, Ozer H: Response of AIDS-related plasmablastic lymphoma (PBL) to bortezomib. J Clin Oncol; 2009 May 20;27(15_suppl):e19562

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response of AIDS-related plasmablastic lymphoma (PBL) to bortezomib.
  • An AIDS-defining illness, PBL comprises 2.6% of AIDS-related lymphomas.
  • They are terminally differentiated B-cell neoplasms, and typically lack common B-cell markers but uniformly express plasma cell markers.
  • Flow cytometry was negative for CD45 and all common epithelial, T-cell and B-cell markers, but was positive for CD138 and p63(VS38c).
  • The diagnosis was stage IVBE PBL.
  • The WHO classifies PBL as a variant of diffuse large B-cell lymphoma.
  • However, studies of their immunophenotype and molecular histogenesis suggest that PBL are more closely related to plasma cell neoplasms.
  • Bortezomib is a proteasome inhibitor widely used in multiple myeloma and mantle cell lymphoma.
  • We chose bortezomib based on our patient's poor performance status and immune function, the desire to avoid combination chemotherapy, and translocations involving the immunoglobulin heavy chain gene locus (8;14) similar to those seen in multiple myeloma(4;14, 14;16) and mantle cell lymphoma(11;14).
  • A shift in the paradigm of treatment of PBL towards agents effective in plasma cell malignancies may be necessary.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961065.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Arias-Mendoza F, Leach MO, Koutcher JA, Griffiths JR, Heerschap A, Glickson JD, O'Connor OA, Brown TR, Cooperative Group for MR Applications in Cancer: Prediction of treatment response in subtypes of non-Hodgkin's lymphoma by in vivo &lt;sup&gt;31&lt;/sup&gt;P MR spectroscopy before treatment. J Clin Oncol; 2009 May 20;27(15_suppl):8565

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prediction of treatment response in subtypes of non-Hodgkin's lymphoma by in vivo <sup>31</sup>P MR spectroscopy before treatment.
  • : 8565 Background: To determine if the intracellular tumor marker of phosphoethanolamine plus phosphocholine normalized by nucleotide triphosphates (PPN) monitored non-invasively by phosphorus MR spectroscopy (<sup>31</sup>P-MRS) correlate with indicators of treatment response in non-Hodgkin's lymphoma (NHL) subtypes.
  • METHODS: The PPN value was obtained in 33 diffuse large B-cell lymphomas (DLBCL), 18 follicular lymphomas (FL) and 16 other types (OT) of NHL using in vivo 3D-localized, <sup>1</sup>H-irradiated <sup>31</sup>P-MRS prior to standard treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961022.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Roberts AW, Wilson W, Gandhi L, O'Connor OA, Rudin CM, Brown JR, Xiong H, Chiu Y, Enschede S, Krivoshik AP: Ongoing phase I studies of ABT-263: Mitigating Bcl-X&lt;sub&gt;L&lt;/sub&gt; induced thrombocytopenia with lead-in and continuous dosing. J Clin Oncol; 2009 May 20;27(15_suppl):3505

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ongoing phase I studies of ABT-263: Mitigating Bcl-X<sub>L</sub> induced thrombocytopenia with lead-in and continuous dosing.
  • : 3505 Background: ABT-263, a novel, oral BH3 mimetic, potently inhibits multiple antiapoptotic Bcl-2 family proteins.
  • Ongoing phase 1 studies of ABT-263 show anti-tumor activity in CLL and some lymphomas (Wilson W et al, ASH. 2008).
  • However, thrombocytopenia (TCP) due to on-target Bcl-X<sub>L</sub> inhibition-induced platelet apoptosis is also observed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961281.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Novais PC, Paula AA, Rodrigues AA Jr, Barione DF, Peria FM, Tirapelli DP, Tucci S Jr, Cologna AJ, Martins AC, Tirapelli LF: Apoptotic genes as a prognostic factor in penile epidermoid carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e22208

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The comprehension of the disease behavior can provides new, non-invasive therapeutic interventions.
  • For this reason, the protein expression of apoptotic genes (caspase-3, caspase-8, bcl-2) were analysed with the immunohistochemistry technique, correlating with tumor grade (I, II and III) and with the patient survival in order to understand the basic mechanism of tumoral transformation.
  • Therefore, this study can contribute with information about this disease.
  • METHODS: The immunohistochemistry reactions on 50 samples of squamous cell carcinoma were carried out with the avidina-biotina-imunoperoxidase method with antigen recovery.
  • The analyses were made using the graduation method 'in crosses' (0 to 4 crosses - no stain to more than 75% of positives cells) and in categories (low, intermediate, high) of the cytoplasm immunoreactivity of the epidermoide penile carcinoma cells.
  • The protein expression of caspase-3 and caspase-8 was lesser in relation to bcl-2, suggesting that the apoptotics rate in this carcinoma is low.
  • The higher expression of the anti-apoptotic protein bcl-2 suggests a higher preservation of the tumoral cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964136.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Leal TB, Schelman W, Traynor A, Kolesar J, Marnosha R, Eickhoff J, Alberti D, Wilding G: A phase I study of R-(-)-gossypol (AT-101) in combination with cisplatin (P) and etoposide (E) in patients with advanced solid tumors and extensive-stage small cell lung cancer (ES-SCLC). J Clin Oncol; 2009 May 20;27(15_suppl):e13502

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of R-(-)-gossypol (AT-101) in combination with cisplatin (P) and etoposide (E) in patients with advanced solid tumors and extensive-stage small cell lung cancer (ES-SCLC).
  • : e13502 Background: AT-101 [R-(-)-gossypol acetic acid] (AT) is an orally-administered BH3 mimetic that lowers the threshold for apoptosis by direct binding to Bcl-2, Bcl-xL, Mc1-1, Bcl-W, and through upregulation of the proapoptotic proteins Noxa and Puma.
  • Bcl- 2 is over-expressed in >80% of SCLC.
  • In vitro study using SCLC cells showed that treatment with EP had synergistic cytotoxic effects in suppression of Bcl-2.
  • METHODS: This study used standard eligibility criteria except patients must not have received prior therapy that inhibits the Bcl-2 family.
  • Four patients had stable disease; two progressive disease and four patients were unevaluable.
  • Subjective and objective evidence of clinical activity has been observed in patients with refractory solid tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961255.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Poiesz B, Reeves J, McNulty W, Maleski J, Holmlund J, Leopold L: Preliminary report of an open-label, multicenter, phase I/II study of AT-101 in combination with docetaxel (D) and prednisone (P) in men with docetaxel refractory prostate cancer. J Clin Oncol; 2009 May 20;27(15_suppl):5145

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 5145 Background: Antiapoptotic Bcl-2 family proteins are overexpressed in castrate resistant prostate cancer (CRPC) and contribute to resistance to therapy.
  • AT-101 is a pan-Bcl-2 inhibitor (Bcl-2, Bcl-X<sub>L,</sub> Bcl-W, and Mcl-1) and potent inducer of proapoptotic proteins.
  • Patients (pts) must have PSA progression per the Bubley criteria or documented disease progression while receiving prior D/P therapy.
  • Radiological assessments were performed at 6-wk intervals for pts with soft tissue disease and bone scans were performed after cycle 6 and at the completion of therapy.
  • Twenty one of 34 pts included in this analysis had measurable disease.
  • Five pts (24%) with measurable disease had a PR or CR by RECIST criteria and one additional patient had tumor shrinkage of 29%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964445.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Wilson W, O'Connor OO, Roberts AW, Czuczman M, Brown J, Xiong H, Xiong H, Chiu Y, Krivoshik A, Enschede S, Humerickhouse R: ABT-263 activity and safety in patients with relapsed or refractory lymphoid malignancies in particular chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). J Clin Oncol; 2009 May 20;27(15_suppl):8574

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ABT-263 activity and safety in patients with relapsed or refractory lymphoid malignancies in particular chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
  • : 8574 Background: ABT-263, a novel, orally bioavailable, BH3 mimetic, binds with high affinity (K<sub>i</sub> ≤ 1nM) and inhibits multiple antiapoptotic Bcl-2 family proteins.
  • ABT-263 displays activity (EC<sub>50</sub> ≤ 1μM) against human lymphoid and small cell lung cancer cell lines.
  • Mechanism based preclinical toxicities include reductions in circulating lymphocytes, apoptosis of circulating platelets, and decreased spermatogenesis, mediated by inhibition of Bcl-2, Bcl-X<sub>L</sub>, and Bcl-w, respectively.
  • 6 pts maintained a ≥50% decrease in circulating lymphocytes for ≥ 2 months and 11 pts have stable disease; of these 5 experienced minor radiographic responses (range of 36% to 49%).
  • In addition, among 40 (M06-814) lymphoma pts, 3 with follicular lymphoma achieved PR and one had a minor response (49% regression).
  • Pharmacodynamic toxicities included dose-dependent thrombocytopenia (TCP) resulting from on-target activity against Bcl-X<sub>L</sub>.
  • CONCLUSIONS: ABT-263 showed favorable PK and safety profiles with anti-tumor activity in relapsed/refractory CLL/SLL and follicular lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962273.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Forde P, Grant C, Smith E, Farrell M, Brett F, Bolger C, Grogan L, Breathnach O: Primary central nervous system lymphoma: An Irish clinical experience. J Clin Oncol; 2009 May 20;27(15_suppl):e13032

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary central nervous system lymphoma: An Irish clinical experience.
  • : e13032 Background: North American studies have demonstrated an increase in incidence of primary CNS lymphoma in recent decades.
  • To our knowledge there have been no studies analyzing primary CNS lymphoma in the Irish setting.
  • METHODS: The records of 78 patients diagnosed with primary CNS lymphoma at our institution between January 1999 and October 2008 were reviewed.
  • Patient's age, sex, and time to diagnosis were noted.
  • Histology and radiology was reviewed for cell of origin, CD20 status, and sites of involvement.
  • Median time from hospital presentation to histological diagnosis was 17 days (4-790).
  • 92% (74) of primary CNS lymphomas were B cell and CD20 positive with 8% (4) being T cell.
  • One-third of patients had multifocal brain involvement by lymphoma.
  • CONCLUSIONS: In comparison with international published series primary CNS lymphoma in Ireland is diagnosed at an older median age, has a more even sex distribution and a relatively higher incidence of T cell origin.
  • Multifocal tumor involvement was also more frequent than in other series possibly indicating later clinical presentations.
  • The wide range in time to diagnosis indicates the difficulties associated with diagnosing this uncommon condition.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962876.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Andorsky DJ, Yamada R, Steward K, De Vos S, Said J, Timmerman J: Expression of programmed death ligand 1 (PD-L1) by non-Hodgkin's lymphomas (NHL) and effect on tumor-associated T cells. J Clin Oncol; 2009 May 20;27(15_suppl):8526

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of programmed death ligand 1 (PD-L1) by non-Hodgkin's lymphomas (NHL) and effect on tumor-associated T cells.
  • : 8526 Background: PD-L1 is expressed on antigen presenting cells and inhibits activation of T cells through its receptor, PD-1.
  • METHODS: PD-L1 expression was analyzed in 16 NHL cell lines by flow cytometry (FC) and in 111 lymphoma specimens by immunohistochemistry (IHC) (n=92) or FC (n=19).
  • In functional studies, irradiated anaplastic large cell lymphoma (ALCL) cells were co-cultured with allogeneic T cells in the presence of anti-PD-L1 blocking antibody, and IFNγ secretion and thymidine incorporation was used to assess T cell function and proliferation.
  • To further test tumor-T cell interactions, malignant ascites from a patient with ALK+ ALCL and peripheral blood mononuclear cells from a patient with leukemic mantle cell lymphoma, both containing PD-L1-expressing tumor cells and tumor-associated T cells, were stimulated with phytohemagglutinin (a polyclonal T cell activator) and incubated with anti-PD-L1 antibody.
  • Levels of 16 inflammatory cytokines were measured as an assessment of T cell activity.
  • RESULTS: All 9 B cell lymphoma lines were negative for PD-L1, while all 5 ALCL cell lines were strongly positive.
  • One T-cell ALL line was positive, and one peripheral T cell lymphoma was negative.
  • Strong PD-L1 staining was detected by IHC in all 14 ALCL specimens and in 83% of diffuse large B cell lymphomas (DLBCL) analyzed (n=35).
  • Activity of allogeneic T cells co-cultured with irradiated ALCL cells, as measured by IFNγ secretion and proliferation, was markedly enhanced in the presence of anti-PD-L1 blocking antibody.
  • In the autologous setting using cultures of ALCL and mantle cell lymphoma specimens containing host T cells, secretion of inflammatory cytokines by tumor-associated T cells, including GMCSF, IFNγ, IL-1, IL-6, IL-8, TNFα, and MIP1α, were increased by incubation with anti-PD-L1 antibody.
  • Blockade of tumor-associated PD-L1 promoted activation of adjacent T cells.
  • PD-L1 may play a role in thwarting an effective anti-tumor immune response and represents an attractive target for lymphoma immunotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960901.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Li G Jr, Zhang Z, Ma X, Sheng W, Zhu J, Cai G, Cai G, Liu M, Gu W, Li J: A pilot study of biological markers (BM) as predictors for response and prognosis in patients (pts) with R0 resected gastric cancer (GC). J Clin Oncol; 2009 May 20;27(15_suppl):e22076

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e22076 Background: To evaluate clinical value of biological markers and their prognostic significance in gastric cancer as well as prediction to clinic outcome; To select preference marker for targeted therapy in high risk patients hence to guide personalized treatment.
  • Preoperative tumor markers include: CEA, AFP, CA199, CA50, CA72-4, CA24-2 and postoperative immunohistochemical examination include: Bax, Bcl-2, P27, CyclinD1, TOPO2, MDR, GST-π, Ki67, AgNOR, EGFR, P21, P53, PCNA, C-myc and Neu were analyzed.
  • Logistic regression analysis showed bcl-2, ki67, c-myc2 and Neu were relative with more nodal involvement.
  • There were different clinical significance with those biomarkers.
  • Univariate analysis showed that clinical staging, level of cyclinD1 and CEA were correlated with OS (p<0.05).
  • CONCLUSIONS: Biological markers may be helpful in predicting the clinical outcome and prognosis for R0 resected gastric cancer patients.
  • Further study are needed to confirm their clinical significance.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963218.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Dummer R, Eichmüller S, Gellrich S, Assaf C, Dreno B, Schiller M, Dereure O, Baudard M, Bagot M, Khammari A, Bleuzen P, Bataille V, Derbij A, Wiedemann N, Waterboer T, Lusky M, Acres B, Urosevic-Maiwald M: Phase II Clinical Trial of Intratumoral Application of TG1042 (Adenovirus-interferon-γ) in Patients With Advanced Cutaneous T-cell Lymphomas and Multilesional Cutaneous B-cell Lymphomas. Mol Ther; 2010 Jun;18(6):1244-1247

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II Clinical Trial of Intratumoral Application of TG1042 (Adenovirus-interferon-γ) in Patients With Advanced Cutaneous T-cell Lymphomas and Multilesional Cutaneous B-cell Lymphomas.
  • : Cutaneous lymphomas (CLs) are a heterogeneous group of lymphoproliferative disorders that are manageable by immunotherapy.
  • Twenty-one patients were enrolled in a prospective open-label, dose-escalation multicenter study evaluating the effects of repeated TG1042 [adenovirus-interferon (IFN)-γ] intralesional injections in patients with primary CLs, of which 18 were of T-cell and 3 of B-cell type.
  • Immune monitoring in the peripheral blood demonstrated systemic immune activation and the induction of antibodies against tumor antigens in some patients without clear association with clinical responses.
  • CLs, in particular B-cell lymphomas with high objective response rates, seem to be excellent targets for this type of immunotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 The American Society of Gene & Cell Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28178498.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Saleh MN, Pitot H, Maleski J, Leopold L, Forero A: Extended phase I trial of the oral pan-Bcl-2 inhibitor AT-101 by multiple dosing schedules in patients with advanced cancers. J Clin Oncol; 2009 May 20;27(15_suppl):e14537

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extended phase I trial of the oral pan-Bcl-2 inhibitor AT-101 by multiple dosing schedules in patients with advanced cancers.
  • : e14537 Background: Over-expression of Bcl-2 family proteins is common in human cancers.
  • Initial trials of the oral, pan-Bcl-2 inhibitor AT-101 showed acute dose limiting toxicity of Gr 3-4 AST/ALT (MTD 40 mg/d) and ileus with prolonged dosing daily (QD) for 21/28 days per cycle (Saleh, NCI/EORTC, 2005; James, ASCO, 2006 and Saleh, ASCO, 2007).
  • Stable disease was reported in 13/37 (35%) pts.
  • One pt with NSCLC continues on study with stable disease for 33 cycles and 2 additional pts were on study with stable disease for 18 and 9 cycles.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963553.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Magić Z, Novković T, Cikota B, Tasić-Radić O, Tarabar O, Stamatović D: Genetic alterations in B-cell non-Hodgkin's lymphoma. Vojnosanit Pregl; 2005 Feb;62(2):87-96

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic alterations in B-cell non-Hodgkin's lymphoma.
  • BACKGROUND: Although the patients with diagnosed B-NHL are classified into the same disease stage on the basis of clinical, histopathological, and immunological parameters, they respond significantly different to the applied treatment.
  • This points out the possibility that within the same group of lymphoma there are different diseases at molecular level.
  • For that reason many studies deal with the detection of gene alterations in lymphomas to provide a better framework for diagnosis and treatment of these hematological malignancies.
  • METHODS: Formalin fixed and paraffin embedded lymph node tissues from 45 patients were examined by different PCR techniques for the presence of IgH and TCR gamma gene rearrangement; K-ras and H-ras mutations; c-myc amplification and bcl-2 translocation.
  • There were 34 cases of B-cell non-Hodgkin's lymphoma (B-NHL), 5 cases of T-cell non-Hodgkin's lymphoma (T-NHL) and 6 cases of chronic lymphadenitis (CL).
  • The mononuclear cell fraction of the peripheral blood of 12 patients with B-NHL was analyzed for the presence of monoclonality at the time of diagnosis and in 3 to 6 months time intervals after an autologous bone marrow transplantation (BMT).
  • RESULTS: The monoclonality of B-lymphocytes, as evidenced by DNA fragment length homogeneity, was detected in 88 % (30/34) of B-NHL, but never in CL, T-NHL, or in normal PBL.
  • Bcl-2 translocation was detected in 7/31 (22.6%) B-NHL specimens, c-myc amplification 9/31 (29%, all were more than doubled), K-ras mutations in 1/31 (3.23%) and H-ras mutations in 2/31 (6.45%) of the examined B-NHL samples.
  • All the patients (12) with B-NHL had dominant clone of B-lymphocyte in the peripheral blood at the time of diagnosis while only in 2 of 12 patients MRD was detected 3 or 6 months after BMT.
  • This technique is also very effecient for tracking minimal residual disease in lymphomas and leukemias and for monitoring clonal evolution in acute and chronic lymphoblastic leukemias and lymphomas.
  • [MeSH-major] Lymphoma, B-Cell / genetics
  • [MeSH-minor] Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor / genetics. Genetic Markers. Humans. Point Mutation. Proto-Oncogenes / genetics. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15787160.001).
  • [ISSN] 0042-8450
  • [Journal-full-title] Vojnosanitetski pregled
  • [ISO-abbreviation] Vojnosanit Pregl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Yugoslavia
  • [Chemical-registry-number] 0 / Genetic Markers
  •  go-up   go-down


92. Gao G, Liang X, Jiang J, Zhou X, Huang R, Chu Z, Zhan Q: A systematic review and meta-analysis of immunochemotherapy with rituximab for B-cell non-Hodgkin's lymphoma. Acta Oncol; 2010;49(1):3-12
PubMed Health. DARE review .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A systematic review and meta-analysis of immunochemotherapy with rituximab for B-cell non-Hodgkin's lymphoma.
  • BACKGROUND: Although some randomized controlled trials had compared the anti-CD20 monoclonal antibody rituximab plus chemotherapy (R-chemo) to chemotherapy alone for B-cell non-Hodgkin's lymphoma, the curative effects of R-chemo were still controversial.
  • A systematic review and meta-analysis was performed to examine the efficacy of using R-chemo compared with the identical chemotherapy alone in the patients with B-cell non-Hodgkin's lymphoma.
  • MATERIAL AND METHODS: Medical databases and conference proceedings were searched for randomized controlled trials which compared R-chemo with chemotherapy alone in patients with newly diagnosed or relapsed B-cell non-Hodgkin's lymphoma.
  • Endpoints were overall survival, overall response, disease control, and adverse events.
  • Superiority was also observed for the patients receiving R-chemo with respect to overall response (RR, 1.17; 95%CI, 1.10-1.25, p <0.00001), complete response (RR, 1.52; 95%CI, 1.27-1.82, p <0.00001), and disease control (RR, 1.36; 95%CI, 1.26-1.46, p <0.00001).
  • R-chemo improved overall survival, overall response and disease control in patients with diffuse large B-cell lymphoma (RR, 1.11, 95%CI: 1.06-1.16, p 0.0001; RR, 1.09, 95%CI: 1.01-1.19, p = 0.03 and RR, 2.00, 95%CI: 1.59-2.53, p <0.00001, respectively) and follicular lymphoma (RR, 1.08, 95%CI: 1.04-1.12, p <0.0001; RR, 1.19, 95%CI: 1.07-1.33, p = 0.001 and RR, 2.58, 95%CI: 1.61-4.12, p 0.0001, respectively).
  • Meanwhile, R-chemo improved overall response in patients with mantle cell lymphoma (RR, 1.22, 95%CI: 1.07-1.40, p = 0.004).
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Clinical Trials as Topic. Humans. Immunotherapy / methods. Rituximab

  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19714523.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 29
  •  go-up   go-down


93. Mitrović Z, Aurer I: [Rituximab in the treatment of B-cell non-Hodgkin lymphoma]. Lijec Vjesn; 2006 Jan-Feb;128(1-2):36-42
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Rituximab in the treatment of B-cell non-Hodgkin lymphoma].
  • [Transliterated title] Rituksimab u lijecenju B-stanicnih ne-Hodgkinovih limfoma.
  • Rituximab, a chimeric anti-CD20 monoclonal antibody, has become a part of standard treatment of B-cell non-Hodgkin lymphoma in the last several years.
  • Depleting CD20+ cells by various mechanisms, it is active as a single agent and particularly when combined with chemotherapy.
  • It is effective in "in vivo" elimination of neoplastic cells from the hematopoetic stem cell transplant.
  • Combination of rituximab and chemotherapy improves response rates in indolent lymphomas and survival in aggressive lymphomas.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell / drug therapy

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16640226.001).
  • [ISSN] 0024-3477
  • [Journal-full-title] Lijec̆nic̆ki vjesnik
  • [ISO-abbreviation] Lijec Vjesn
  • [Language] hrv
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 71
  •  go-up   go-down


94. Visani G, Isidori A: Nonpegylated liposomal doxorubicin in the treatment of B-cell non-Hodgkin's lymphoma: where we stand. Expert Rev Anticancer Ther; 2009 Mar;9(3):357-63
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonpegylated liposomal doxorubicin in the treatment of B-cell non-Hodgkin's lymphoma: where we stand.
  • Anthracyclines, including doxorubicin, are widely used in the treatment of B-cell non-Hodgkin's lymphoma (NHL).
  • However, their clinical potential is limited by their cardiotoxic adverse effects, which include cardiomyopathy and congestive heart failure.
  • Nonpegylated liposomal doxorubicin produced a promising response rate when substituted for conventional doxorubicin in the cyclophosphamide, doxorubicin, vincristine and prednisolone regimen in the treatment of patients with NHL either at diagnosis or at relapse.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Doxorubicin / administration & dosage. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cyclophosphamide / administration & dosage. Dose-Response Relationship, Drug. Humans. Liposomes. Lymphoma, AIDS-Related / drug therapy. Middle Aged. Prednisolone / administration & dosage. Vincristine / administration & dosage. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19275512.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Liposomes; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone
  • [Number-of-references] 31
  •  go-up   go-down


95. Corapçioglu F, Basar EZ, Demirel A, Inan N, Babaoğlu K, Karakurt H, Kus E, Aksu G: Granulomatous reaction in mediastinal B-cell non-Hodgkin lymphoma and intracardiac thrombosis. Pediatr Hematol Oncol; 2008 Apr-May;25(3):217-26
MedlinePlus Health Information. consumer health - Heart Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulomatous reaction in mediastinal B-cell non-Hodgkin lymphoma and intracardiac thrombosis.
  • Epithelioid cell granulomas may be associated with several neoplasms.
  • Lymphomas may mimic or are associated with epithelioid granulomas.
  • In this article the authors report a child with granulomatous reaction in B cell non-Hodgkin lymphoma and intracardiac thrombosis.
  • Although cancer alone is a risk factor for thromboembolism, thrombosis is a multifactorial disorder with both hereditary and acquired risk factors.
  • This is the first reported case of intracardiac thrombosis with MTHFR A1298C and factor XIII V34L mutations together with granulomatous reaction in non-Hodgkin lymphoma.
  • [MeSH-major] Granuloma / complications. Heart Diseases / etiology. Lymphoma, B-Cell / complications. Mediastinal Neoplasms / complications. Thrombosis / etiology


96. Blasco H, Chatelut E, de Bretagne IB, Congy-Jolivet N, Le Guellec C: Pharmacokinetics of rituximab associated with CHOP chemotherapy in B-cell non-Hodgkin lymphoma. Fundam Clin Pharmacol; 2009 Oct;23(5):601-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacokinetics of rituximab associated with CHOP chemotherapy in B-cell non-Hodgkin lymphoma.
  • We carried out a pilot pharmacokinetic study in 10 patients with B-cell non-Hodgkin lymphoma treated with rituximab associated with chemotherapy on a three-weekly basis.
  • [MeSH-major] Antibodies, Monoclonal / pharmacokinetics. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Antigens, CD19 / immunology. B-Lymphocytes / cytology. B-Lymphocytes / immunology. Cyclophosphamide / administration & dosage. Cyclophosphamide / pharmacokinetics. Cyclophosphamide / therapeutic use. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Doxorubicin / pharmacokinetics. Doxorubicin / therapeutic use. Drug Administration Schedule. Enzyme-Linked Immunosorbent Assay. Humans. Infusions, Intravenous. Lymphocyte Count. Middle Aged. Neoplasm Staging. Pilot Projects. Prednisone / administration & dosage. Prednisone / pharmacokinetics. Prednisone / therapeutic use. Rituximab. Time Factors. Vincristine / administration & dosage. Vincristine / pharmacokinetics. Vincristine / therapeutic use. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19659797.001).
  • [ISSN] 1472-8206
  • [Journal-full-title] Fundamental & clinical pharmacology
  • [ISO-abbreviation] Fundam Clin Pharmacol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD19; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


97. Aref S, Mossad Y, El-Khodary T, Awad M, El-Shahat E: Cyclin Dl expression in B-cell non Hodgkin lymphoma. Hematology; 2006 Oct;11(5):365-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclin Dl expression in B-cell non Hodgkin lymphoma.
  • Disorders of the cell cycle regulatory machinery play a key role in the pathogenesis of cancer.
  • Over-expression of cyclin D1 protein has been reported in several solid tumors and certain lymphoid malignancies, but little is known about the effect of its expression on clinical behavior and outcome in B-cell Non-Hodgkin lymphoma (NHL).
  • In this study, we investigated the expression of cyclin Dl in group of patients with NHL and correlated the results with the clinical and laboratory data.
  • Cyclin Dl over expression was detected in 10 out of 46 (21.7%) patients; they were 5/5-mantle cell lymphoma (MCL) (100%) and 5/28 large B-cell lymphoma (17.8%).
  • The clinical signs (hepatomegaly, splenomegaly and B-symptoms, clinical staging) and laboratory data (hemoglobin, white cell count (WBCs), platelet count, and bone marrow infiltration) were not significantly different between NHL subgroup with cyclin Dl over expression and that with normal cyclin Dl expression.
  • Cyclin Dl over expression was evident among all cases of MCL and few cases of large B-cell lymphoma.
  • Cyclin Dl over expression might be used as adjuvant tool for diagnosis of MCL; has role in NHL biology and is bad prognostic index in NHL.
  • [MeSH-major] Cyclin D1 / genetics. Gene Expression Regulation, Neoplastic. Lymphoma, B-Cell / diagnosis


98. Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM: Malignant B cells skew the balance of regulatory T cells and TH17 cells in B-cell non-Hodgkin's lymphoma. Cancer Res; 2009 Jul 1;69(13):5522-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant B cells skew the balance of regulatory T cells and TH17 cells in B-cell non-Hodgkin's lymphoma.
  • Using biopsy specimens from patients with B-cell non-Hodgkin's lymphoma, we observed a significantly low frequency of T(H)17 cells, including several samples with no detectable amount of interleukin (IL)-17-producing cells present in the tumor microenvironment.
  • We found that, in the absence of lymphoma B cells, treatment with IL-1beta/IL-6 or lipopolysaccharide (LPS) enhanced IL-17 expression in CD4(+) T cells and this enhancement was attenuated when CD4(+) T cells were cocultured with lymphoma B cells.
  • Blockade of CD27-CD70 or CD28-CD80/86 interactions by anti-CD70 or anti-CD80/86 antibodies restored LPS-mediated induction of IL-17 expression in CD4(+) T cells cocultured with lymphoma B cells.
  • Because a subset of lymphoma B cells express IL-2 and given that IL-2 signaling is critically important in the development of regulatory T (T(reg)) cells, we tested the role of IL-2 signaling in T(H)17 cell development.
  • We found that treatment with anti-IL-2 antibody to interrupt IL-2 signaling significantly inhibited Foxp3 expression in CD4(+) T cells.
  • In contrast, interruption of IL-2 signaling up-regulated IL-17 expression in CD4(+) T cells and restored lymphoma-mediated down-regulation of IL-17-producing cells.
  • Furthermore, the reversal of T(reg) cell activity by LPS or CpG-A resulted in an enhancement of IL-17-producing cells.
  • Taken together, our study indicated that lymphoma B cells play an important role in skewing the balance between T(reg) and T(H)17 cells resulting in the establishment of a profoundly inhibitory tumor microenvironment.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int Immunol. 2004 Dec;16(12):1769-80 [15520045.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Science. 2005 Aug 26;309(5739):1380-4 [16123302.001]
  • [Cites] Nat Immunol. 2005 Nov;6(11):1133-41 [16200068.001]
  • [Cites] Nat Immunol. 2005 Nov;6(11):1123-32 [16200070.001]
  • [Cites] Blood. 2006 May 1;107(9):3639-46 [16403912.001]
  • [Cites] Nature. 2006 May 11;441(7090):235-8 [16648838.001]
  • [Cites] Br J Haematol. 2006 Sep;134(6):596-601 [16889618.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):10145-52 [17047079.001]
  • [Cites] Anticancer Res. 2006 Nov-Dec;26(6B):4213-6 [17201135.001]
  • [Cites] Immunity. 2007 Mar;26(3):371-81 [17363300.001]
  • [Cites] Breast Cancer Res. 2007;9(1):R15 [17261184.001]
  • [Cites] J Immunol. 2007 Jun 1;178(11):6730-3 [17513719.001]
  • [Cites] Nat Immunol. 2007 Jun;8(6):639-46 [17486092.001]
  • [Cites] Science. 2007 Jul 13;317(5835):256-60 [17569825.001]
  • [Cites] Nature. 2007 Jul 26;448(7152):480-3 [17581589.001]
  • [Cites] J Exp Med. 2007 Aug 6;204(8):1849-61 [17635957.001]
  • [Cites] Nat Immunol. 2007 Sep;8(9):950-7 [17676044.001]
  • [Cites] Nat Immunol. 2007 Sep;8(9):942-9 [17676045.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2537-44 [17615291.001]
  • [Cites] Arthritis Rheum. 2007 Sep;56(9):2936-46 [17763419.001]
  • [Cites] Eur J Immunol. 2007 Nov;37(11):3155-63 [17918200.001]
  • [Cites] Front Biosci. 2008;13:1440-6 [17981641.001]
  • [Cites] Int Immunopharmacol. 2007 Dec 15;7(13):1819-24 [17996694.001]
  • [Cites] J Immunol. 2008 Jan 1;180(1):122-9 [18097011.001]
  • [Cites] J Immunol. 2008 Jan 1;180(1):214-21 [18097022.001]
  • [Cites] Clin Immunol. 2008 Apr;127(1):89-97 [18294918.001]
  • [Cites] Arthritis Rheum. 2008 Mar;58(3):875-87 [18311821.001]
  • [Cites] Gut. 2008 Jun;57(6):772-9 [17965063.001]
  • [Cites] Cancer Res. 2008 May 15;68(10):3915-23 [18483277.001]
  • [Cites] J Immunol. 2008 Jun 15;180(12):7948-57 [18523258.001]
  • [Cites] Blood. 2008 Jul 15;112(2):362-73 [18354038.001]
  • [Cites] J Exp Med. 2008 Aug 4;205(8):1903-16 [18663128.001]
  • [Cites] Blood. 2008 Sep 15;112(6):2340-52 [18617638.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Oct 7;105(40):15505-10 [18832156.001]
  • [Cites] Nat Med. 2007 Jun;13(6):711-8 [17496900.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):720-6 [11157023.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Apr 6;282(3):735-8 [11401524.001]
  • [Cites] Ann Oncol. 2002;13 Suppl 1:52-6 [12078904.001]
  • [Cites] Science. 2003 Feb 14;299(5609):1033-6 [12532024.001]
  • [Cites] Prostate. 2003 Aug 1;56(3):171-82 [12772186.001]
  • [Cites] J Exp Med. 2003 Jul 21;198(2):235-47 [12874257.001]
  • [Cites] J Exp Med. 2003 Dec 15;198(12):1875-86 [14676299.001]
  • [Cites] J Cell Mol Med. 2003 Oct-Dec;7(4):472-4 [14754516.001]
  • [Cites] Annu Rev Immunol. 2004;22:531-62 [15032588.001]
  • [Cites] J Immunol. 2004 May 1;172(9):5149-53 [15100250.001]
  • [Cites] Int J Cancer. 2004 Oct 20;112(1):113-20 [15305382.001]
  • [Cites] J Exp Med. 2005 Jan 3;201(1):127-37 [15630140.001]
  • (PMID = 19509224.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA097274-070004; United States / NCI NIH HHS / CA / CA97274; United States / NCI NIH HHS / CA / R01 CA092104; United States / NCI NIH HHS / CA / CA092104-01A1; United States / NCI NIH HHS / CA / CA92104; United States / NCI NIH HHS / CA / CA097274-080004; United States / NCI NIH HHS / CA / CA097274-070004; United States / NCI NIH HHS / CA / R01 CA092104-01A1; United States / NCI NIH HHS / CA / P50 CA097274-080004; United States / NCI NIH HHS / CA / P50 CA097274; United States / NCI NIH HHS / CA / R01 CA092104-05A2; United States / NCI NIH HHS / CA / CA092104-05A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / Interleukin-17; 0 / Interleukin-2; 0 / Interleukin-23; 0 / Transforming Growth Factor beta
  • [Other-IDs] NLM/ NIHMS145634; NLM/ PMC2764404
  •  go-up   go-down


99. Kassam S, Montoto S: Oncologic, endocrine & metabolic emerging drugs in B-cell non-Hodgkin's lymphoma. Expert Opin Emerg Drugs; 2008 Jun;13(2):323-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncologic, endocrine & metabolic emerging drugs in B-cell non-Hodgkin's lymphoma.
  • BACKGROUND: The incidence of non-Hodgkin's lymphoma, of which B-cell neoplasms are the commonest, has been increasing over the last 20 years.
  • However, treatment failure with disease recurrence remains a major problem.
  • OBJECTIVES: To review preclinical and clinical data on novel molecularly targeted therapies that show promise for the treatment of B-cell NHL.
  • RESULTS/CONCLUSION: Large numbers of new drugs are at various stages of preclinical and clinical development.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Drug Delivery Systems. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Drug Design. Female. Humans. Immunotherapy. Lymphoma, Follicular / drug therapy. Lymphoma, Follicular / physiopathology. Lymphoma, Mantle-Cell / drug therapy. Lymphoma, Mantle-Cell / physiopathology. Male. Recurrence. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18537524.001).
  • [ISSN] 1744-7623
  • [Journal-full-title] Expert opinion on emerging drugs
  • [ISO-abbreviation] Expert Opin Emerg Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 149
  •  go-up   go-down


100. Li B, Zhong MZ, Tang TF, Liu W, Huang J: [Correlation of cyclooxygenase-2 expression to P-glycoprotein expression in B-cell non-Hodgkin's lymphoma]. Ai Zheng; 2007 Aug;26(8):851-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlation of cyclooxygenase-2 expression to P-glycoprotein expression in B-cell non-Hodgkin's lymphoma].
  • BACKGROUND & OBJECTIVE: The overexpression of P-glycoprotein (P-gp) plays an important role in the chemoresistance of relapsed lymphoma.
  • This study was to observe the expression and correlation of COX-2 and P-gp in B-cell non-Hodgkin's lymphoma (B-NHL), and to investigate their correlations to clinicopathologic features of B-NHL.
  • [MeSH-major] Cyclooxygenase 2 / metabolism. Lymphoma, B-Cell / metabolism. P-Glycoprotein / metabolism
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17697546.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / P-Glycoprotein; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down






Advertisement